JPH0354647B2 - - Google Patents
Info
- Publication number
- JPH0354647B2 JPH0354647B2 JP58186648A JP18664883A JPH0354647B2 JP H0354647 B2 JPH0354647 B2 JP H0354647B2 JP 58186648 A JP58186648 A JP 58186648A JP 18664883 A JP18664883 A JP 18664883A JP H0354647 B2 JPH0354647 B2 JP H0354647B2
- Authority
- JP
- Japan
- Prior art keywords
- liquid preparation
- calcitonin
- preparation according
- nasal
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 claims description 67
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 56
- 102000055006 Calcitonin Human genes 0.000 claims description 33
- 108060001064 Calcitonin Proteins 0.000 claims description 33
- 229960004015 calcitonin Drugs 0.000 claims description 32
- 108010068072 salmon calcitonin Proteins 0.000 claims description 24
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 21
- 210000002850 nasal mucosa Anatomy 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000007922 nasal spray Substances 0.000 claims description 15
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 12
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 12
- 229940097496 nasal spray Drugs 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 claims description 3
- 108700032313 elcatonin Proteins 0.000 claims description 3
- 229960000756 elcatonin Drugs 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 235000015277 pork Nutrition 0.000 claims description 2
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940045644 human calcitonin Drugs 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 13
- 150000002170 ethers Chemical class 0.000 description 13
- -1 polyoxyethylene Polymers 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 8
- 238000011109 contamination Methods 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000007918 intramuscular administration Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- ZFGOPJASRDDARH-UHFFFAOYSA-N 3-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C(C2)C1(C)CCC2OC1CC2=CCC3C4CCC(C(C)CCCC(C)C)C4(C)CCC3C2(C)CC1 ZFGOPJASRDDARH-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 3
- 229960004926 chlorobutanol Drugs 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 2
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical group C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 2
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 2
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 2
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 2
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Chemical group C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical group C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 2
- 229940058690 lanosterol Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 241000316144 Macrodon ancylodon Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 125000002328 sterol group Chemical group 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Description
ãã®çºæã¯ãæå¹æåãšããŠã«ã«ã·ããã³ãå«
ãæ°èŠãªïŒã¬ã¬ãã¹ïŒè£œå€çµæç©ã«é¢ãããã®ã§
ããã ã«ã«ã·ããã³é¡ã¯ãçš®ã ã®åšç¥ã®å»è¬çšéã«çš
ãããããå»è¬æŽ»æ§ãæããå ¬ç¥ã®é·éããªãã
ãããå«ãã§ãããäŸãã°ãµãŒã¢ã³ïŒããã»ãŸã
é¡ïŒããã³ããªãã«ã«ã·ããã³ãå«ããŠãçš®ã ã®
ã«ã«ã·ããã³ãåžè²©ãããäŸãã°ããŒãžãšãã
ç ãé«ã«ã«ã·ãŠã è¡çããã³éªšå€åçã®æ²»çã«åº
ãçšããããŠããã ããããããªãããããäžè¬ã«ããã§ãããã
ã«ãã«ã«ã·ããã³é¡ã®å¥œé©ãã€æå¹ãªæäžæ段ã«
ã¯å€ãã®å°é£æ§ãååšãããããªããããã§ãã
ãããã«ã«ã·ããã³ã¯æäžã«éãå解ããæãã
äœæ¶²äžã«ç§»è¡ããã®ãå°é£ã§ããããã®çç±ã
ããæå¹ãªæ²»çãè¡ãªãããã®äžè¬çãªå¯äžã®çµ
è·¯ã¯ãè žç®¡å€æäžã§ãã€ããäžè¬ã«ãæäžæ³ã¯æ³š
å°ã§ãã€ãããã®ãããªæäžæ³ã¯äœã奜ãŸãããª
ããéåžžã®ééã§æäžãè¡ãªã€ãå Žåæ£è ã«èã
ãèŠçãäžããããããã€ãŠãæ£è ã®äžæºãå°ãª
ãã奜ãŸããã¯å®¹æã«èªå·±æäžã§ãåæã«èšåºç
æ²»çã«å åæå¹ãªçäœå å©çšçãéæã§ããå®è¡
å¯èœãªä»£æ¿æ段ããé·å¹Žã®é倧ããªç®æšãšãªã€ãŠ
ããã ãã®çºæè ã¯ãã«ã«ã·ããã³é¡ãçµéŒ»ã«ãŒãã§
æäžããããšãããªãã¡éŒ»ç²èã«é©çšããããšã«
ãããæå¹ãªèšåºçæ²»çãå¯èœãªããšãçºèŠã
ãã詳ããè¿°ã¹ããšããã®çºæè ã¯ããã®çºæã®
ç¹æ®ãªæè¡ã«ãããšãæšæºççè泚å°ã«ããæäž
ã§åŸãããã®ãšåçã®çäœå å©çšæ§ã¬ãã«ããå
åå¿å®¹æ§å ã«ããå®çšççšéã¬ãã«ã®éŒ»å æäžã§
åŸãããããšãç¥ã€ããããã«ãäŸãã°ãµãŒã¢ã³
ã«ã«ã·ããã³ããã³ããªãã«ã«ã·ããã³èªå°äœã
ïŒïŒïŒâAsuâããªãã«ã«ã·ããã³ïŒä»¥äžããšã«
ã«ããã³ãšããïŒãç¹ã«ãµãŒã¢ã³ã«ã«ã·ããã³ãã
ãã®çºæã®æ瀺ã«ããçµéŒ»ã«ãŒãã§æäžããã®ã«
ç¹ã«å¥œé©ã§ããããšãç¥ã€ãã çµéŒ»ã«ãŒãã¯ãäŸãã°éŒ»çšã¢ããªã±ãŒã¿ãŒã«ã
ã錻çšã¹ãã¬ã€ãŸãã¯ç¹æ¶²æäžã«ããæ£è èªèº«ã«
ãã容æã«å®æœã§ãããç°¡åã§èŠçã®å°ãªãæäž
æ³ãæäŸããããã®ã«ãŒãã¯ãäžè¬ã«å»åž«ã®ç£ç£
äžã«è¡ãªãããè žç®¡å€æäžã«èŒã¹ãŠæããã«å€§ã
ãªå©ç¹ãæããã çµéŒ»ã«ãŒãæäžã¯äŸãã°æ³šå°ã®ãããªåŸæ¥äžè¬
ã«è¡ãªãããè žç®¡å€æäžããæããã«æå©ã§ãã
ãã錻çšæäžåœ¢æ ã«çšããçµæç©ã«ã¯æ°å€ãã®é£
ç¹ããããïŒã€ã®åé¡ãç¹ã«ã«ã«ã·ããã³ã®ãã
ãªè€åè¬å€ã®éŒ»å æäžã«ãããŠéèŠãªåé¡ã¯ãäŸ
ãã°ç åæ§ãŸãã¯ä»ã®äžéœåãªåŸ®çç©ã«ããæ±æ
ãé¿ããããã«å åäž¡ç«å¯èœã§æå¹ãªæ段ã®äŸçµŠ
ã§ãããæ±æããã®ä¿è·ã®ããã®æå¹æåãšäž¡ç«
å¯èœã§æå¹ãªé²è å€ã¯ãç¹ã«æ±æã®å±éºæ§ã極ã
ãŠé«ã錻çšå»è¬çµæç©ã«ãããŠæ¥µããŠéèŠã§ã
ããé²è å€ã¯åœåã®æ±æåé¿ãäŸãã°è£œå€äžãã
ã³å®¹åšãžã®çµæç©å å¡«äžã ãã§ãªãã䜿çšäžãç¹
ã«ïŒåã®å®¹åšïŒã¢ããªã±ãŒã¿ãŒããã®å€åæäžã
å¿ èŠãªå Žåã®äœ¿çšäžã«ç¶ãæ±æåé¿ã®ããã«å¿ èŠ
ã§ããããã°ãã°ããã§ããããã«ã錻çšã¢ããª
ã±ãŒã¿ãŒã䜿çšåã«æ°ãæãä¿ç®¡ãããå Žåã«ã
ç¹ã«åé¡ãçããããã®æéã«ãäŸãã°ã¢ããªã±
ãŒã¿ãŒå å£ãžã®åžåãç±å解ããŸãã¯é²è å€ãã
ãçšåºŠé床ã®æ®çºæ§ããã€å Žåãã¢ããªã±ãŒã¿ãŒ
ããã®æŒåºã«ãããéžæããé²è å€ãç¡å¹ã«ãªã
åŸããããã«ãå®éã®äœ¿çšæéã«ãïŒããã³ïŒå
ã®ã¢ããªã±ãŒã¿ãŒããã®å€åæäžãäºå®ããŠãã
å Žåæ°æ¥ãªããæ°é±éã«ãããæéã«ãïŒã¢ããª
ã±ãŒã¿ãŒå ã«äžéœåãªåŸ®çç©ãŸãã¯æ±æç©ãå€æ°
ãŸãã¯éŒ»åããæŒã蟌ã¿ãããã¯æµžå ¥ããããã
ãããããŸããçµæç©ã¯äŸãã°èŒžéãããã¯ä¿ç®¡
äžã«çæéã®é«æž©ã«ãããããããšãããã äžèšã®é£ç¹ã«å ããŠã錻å é©çšã®ããã«éçºã
ãå»è¬çµæç©ã¯åæã«ãç¹ã«çŽæ¥é©çšãããéšäœ
ã«å¯ŸããŠé©åºŠã®å¿å®¹æ§ããããªããã°ãªããªãã
äŸãã°ã錻ç²èãåºæ¿ããŠã¯ãªããïŒäŸãã°åºã
æããäžããŠã¯ãªããïŒã现æ¯ã®æ¯ååæ°ãæžå°
ããŠã¯ãªããªãã ã«ã«ã·ããã³å€çµæç©ã«çšãåŸããã®ãšããŠã
極ããŠå€æ°ã®åšç¥ã®é²è å€ãæåºãããŠãããã
ãããå®éšã®çµæã«ã«ã·ããã³ã®éŒ»çšã¹ãã¬ã€ã«
å®çšããã«ã¯ãã¹ãŠã奜é©ã§ã¯ãªãããšãå€æã
ããäŸãã°ãã«ã«ã·ããã³ã®éŒ»çšã¹ãã¬ã€å€çµæ
ç©äž0.6ïŒ ã®ã¯ãã«ãã¿ããŒã«ã¯ãè©ŠéšèPen.ste
ckiiã«å¯ŸããŠã现èæ°ã0.1ïŒ ä»¥äžã«æžããããš
ãå¿ èŠãªïŒæ¥é以äžã«ããã€ãŠäžå åãªæŽ»æ§ãã
瀺ããªãã€ããããã«ãã¯ãã«ãã¿ããŒã«ã¯ããŽ
ã æ ãšéŒ»çšã¹ãã¬ã€ã¢ããªã±ãŒã¿ãŒã®ã¹ãã¬ã€ã
ã³ããšã³ãã®éã«çšããããä»ã®ãžãšã€ã³ããå·
ããããšãå€æããã ãã®äžã«ãã¯ãã«ãã¿ããŒã«ã¯ãã·ãŠãã³ã¹
çãActa Otolarrng.70å·»16ïŒ28ïŒ1970幎ïŒãã€
ã¯ãããªããªã·ãã°ã©ãæ³ã«ãããšã0.6ïŒ ã«ã
ããŠãã©ããæ°ç®¡ã®ç¹æ¯æ¯ååæ°ã20åéã«50ïŒ
以äžæå¶ãããããã¯ããŸãã«èæ ®ãããã¹ãæ¬
ç¹ã§ããã ãã®çºæã«ãããšãé©ãã¹ãããšã«ãå¡©åãã³
ã¶ã«ã³ããŠã ãå ±æåã§ããé²è å€ãšããŠçšãã
ããšã«ããã錻å é©çšã«å¿ èŠãªé«åºŠã®å®å®æ§ãšå¿
容æ§ãæããäŸãã°éŒ»çšã¹ãã¬ã€ã¢ããªã±ãŒã¿
ãŒãããªãã¡äŸãã°æ°æ¥ãŸãã¯æ°é±éã«ããã€ãŠ
äžé£ã®åå¥çšéã®æŸåºãå¯èœãªã¢ããªã±ãŒã¿ãŒã«
ããå€åæäžã«æ¥µããŠå¥œé©ãªãã«ã«ã·ããã³ãæ
å¹æåãšããå»è¬çµæç©ãåŸãããããšãå€æã
ããé©ãã¹ãããšã«ããŸãå¡©åãã³ã¶ã«ã³ããŠã
ã®äœ¿çšã¯ãé²è å€ãšããŠçšããã«å¿ èŠãªæ¥µããŠäœ
æ¿åºŠã«ãããŠããã«ã«ã·ããã³å«æçµæç©ã®çµéŒ»
åžåç¹æ§ã«æçãªå©ç¹ãããããããããã€ãŠéŒ»
å é©çšã§åŸãããã«ã«ã·ããã³ã®çäœå å©çšæ§ã
å¢åŒ·ããããšãå€æããã ãããã€ãŠããã®çºæã¯ã () ã«ã«ã·ããã³ãããã³ () å¡©åãã³ã¶ã«ã³ããŠã ãã ()錻ç²èã«é©çšããã«é©ãã液äœåžéå€ãŸãã¯
æ äœäžã«å«ãŸããŠãªãã 錻å æäžçšå»è¬çµæç©ãæäŸãããã®ã§ããã ãã®æ现æžã«ãããŠããã«ã«ã·ããã³ãã®èªã¯
åºçŸ©ã§çšãããã®ãšãã倩ç¶ã«ç£ããã«ã«ã·ãã
ã³ã ãã§ãªãããã®å»è¬æŽ»æ§ãæããèªå°äœãã
ã³é¡çžäœãäŸãã°å€©ç¶ã«ç£ãããã®ã«ååšããïŒ
åãŸãã¯ïŒå以äžã®ããããæ®åºã眮æããããŸ
ãã¯ïŒ®âãããã¯ïŒ£æ«ç«¯ã修食ããããã®ãå«ã
ãã®ãšããã ãã®çºæã§çšããã«å¥œé©ãªã«ã«ã·ããã³ã¯ããµ
ãŒã¢ã³ãã²ãšããã³è±ã«ã«ã·ããã³ãããã³ãšã«
ã«ããã³ã§ããããããã®ååç©ã¯äœããåžè²©ã
ããŠãããæç®äžã«ãã®å»è¬ãšããŠã®æ§è³ªãšå ±ã«
詳现ã«èšèŒãããŠããã åèšã®ããã«ããµãŒã¢ã³ã«ã«ã·ããã³ã®éŒ»å é©
çšã«ãããäŸãã°çäœå å©çšæ°Žæºããã³è¡æŒ¿å å
åšæéã«ãããŠã極ããŠè¯å¥œãªçµæãåŸãããã ãããã€ãŠããµãŒã¢ã³ã«ã«ã·ããã³ã¯ãã®çºæ
ã§çšããã«æãé©ããã«ã«ã·ããã³ã§ããã ãã®çºæã§çšããã«ã«ã·ããã³ã¯ãéé¢äœããŸ
ãã¯å»è¬äžèš±å®¹ãããå¡©ããŸãã¯ã³ã³ãã¬ãã¯
ã¹ãäŸãã°å»è¬äžèš±å®¹ãããé žä»å å¡©ã®åœ¢ã®äœã
ã§ãããããã®çºæã§çšããé©åœãªé žä»å å¡©ã«
ã¯ãäŸãã°å¡©é žå¡©ããã³é ¢é žå¡©ãå«ãŸããã å¡©åãã³ã¶ã«ã³ããŠã ã¯ãå ¬ç¥ã®äžè¬åŒC6H5
âCH2âNRïŒCH3ïŒ2ClïŒïŒ²ã¯C8H17ãªããC18H37
ã§ããïŒã§ä»£è¡šãããïŒçŽã¢ã³ã¢ããŠã å¡©ã®æ··å
ç©ã«äžè¬çã«äœ¿çšãããå称ã§ããããã®çºæã®
çµæç©äžå¡©åãã³ã¶ã«ã³ããŠã æåã®å¥œãŸããæ¿
床ã¯ãå šçµæç©äžçŽ0.002ãªãã0.02ïŒ ã代衚ç
ã«ã¯çŽ0.01ïŒ ïŒééïŒå®¹éïŒã§ããã ãã®çºæã«ãããšãäžèšã®çµæç©ã¯éŒ»ç²èã«ç¹
液ãŸãã¯ã¹ãã¬ã€ã®äœãã«ãã€ãŠãé©çšã§ããã
ããããåŸè¿°ã®ããã«ãã¹ãã¬ã€ããªãã¡åŸ®çŽ°å
å²æ»Žã®åœ¢ã§é©çšããã®ãæã奜ãŸããã å¿è«ããã®çºæã®çµæç©ã¯ä»ã®æåãç¹ã«äžé£
ã®å»è¬äžèš±å®¹ãããåžžçšçé¢æŽ»æ§å€ã«å±ããæå
ãå«ãããšãã§ããã ãã®çºæã®çµæç©ã§çšãã液äœåžéå€ãŸãã¯æ
äœïŒïŒã¯æ°ŽïŒè£œå€çšïŒãããªãã®ã奜ãŸããã
æã奜ãŸããã®ã¯ãé£å¡©æ°Žã§ããããã®çºæã®çµ
æç©ã¯ãçµéŒ»ã«ãŒãã§æäžã§ããããã«è£œå€ãã
ãããã®ç®çã®ããã«ããã®çµæç©ã¯äŸãã°æå°
éã®ææã«ããå¥ã®æåãŸãã¯è³Šåœ¢å€ãäŸãã°å¥
ã®é²è å€ãŸãã¯äŸãã°ã«ããšã€ã³ã®ãããªçŽ°æ¯åº
æ¿å€ãå«ãããšãã§ãããäžè¬ã«éŒ»å é©çšã«ã¯åŒ±
é žæ§PHã奜ãŸããããã®çºæã®çµæç©ã¯çŽïŒãªã
ãïŒã®PHããã€ã®ã奜ãŸãããçŽ3.5ãªããçŽ4.5
ã®PHãæã奜ãŸãããPHã®èª¿ç¯ã¯ãé©åœãªé žãäŸ
ãã°å¡©é žãå ããŠè¡ãªãããšãã§ããã ãã®çºæã®çµæç©ã¯ãŸããé©åœãªç匵æ§ããã³
ç²åºŠããã€ããšãå¿ èŠãšããããã®çµæç©ã¯ãçŽ
260ãªããçŽ380ïœOsïœïŒãªããã«ã®æ»²éå§ãã
ã€ã®ã奜ãŸããããã®çºæã®çµæç©ã«ãããææ
ã®ç²åºŠã¯ãåã ã®æäžåœ¢æ ãäŸãã°æäžãç¹éŒ»æ¶²
ã§ããã錻å çšã¹ãã¬ã€ã§ãããã«ãã€ãŠç°ãª
ããç¹éŒ»æ¶²ã§ã¯ãé©åœãªç²åºŠã¯çŽïŒãªããçŽ40Ã
10-3PaSã§ããã錻å çšã¹ãã¬ã€ã§ã¯ãç²åºŠã¯ïŒ
Ã10-3PaS以äžãäŸãã°ïŒãªããïŒÃ10-3PaSã
é©åœã§ããã ãã®çºæã®çµæç©ãåžžçšã®çé¢æŽ»æ§å€ãå«ãå Ž
åéã€ãªã³çé¢æŽ»æ§å€ã奜ãŸãããç¹ã«å¥œãŸãã
çé¢æŽ»æ§å€ã¯ãäŸãã°äžè¬åŒïŒïŒ ROãâïŒCH2ïŒoâãâx ïŒïŒ ïŒåŒäžãROã¯é«çŽã¢ã«ã³ãŒã«ãç¹ã«ã©ãŠãªã«ãŸ
ãã¯ã»ãã«ã¢ã«ã³ãŒã«ã®ãããªé«çŽã¢ã«ã«ããŒã«
ãŸãã¯ã¢ã«ãã«ããšããŒã«ã®æ®åºããŸãã¯ã¹ãã
ãŒã«æ®åºãç¹ã«ã©ãã¹ãããŒã«ããžãããã³ã¬ã¹
ãããŒã«ãŸãã¯ã³ã¬ã¹ãããŒã«æ®åºã§ããïŒ ã§ç€ºãããããªãªãã·ã¢ã«ãã¬ã³é«çŽã¢ã«ã³ãŒã«
ãšãŒãã«ã䞊ã³ã«ãã®ãããªãšãŒãã«ã®ïŒçš®ä»¥äž
ã®æ··åç©ã§ããããã®çºæã§çšããã«å¥œé©ãªããª
ãªãã·ã¢ã«ãã¬ã³ãšãŒãã«ã¯ãããªãªãã·ãšãã¬
ã³ããã³ããªãªãã·ãããã¬ã³ãšãŒãã«ïŒããªã
ã¡äžåŒäžïœãïŒãŸãã¯ïŒïŒãç¹ã«ããªãªãã·ãšã
ã¬ã³ããã³ããªãªãã·ãããã¬ã³ã©ãŠãªã«ãã»ã
ã«ãããã³ã³ã¬ã¹ããªã«ãšãŒãã«ã䞊ã³ã«ãã®ã
ããªãšãŒãã«ã®ïŒçš®ä»¥äžã®æ··åç©ã§ããã ãããã®ãšãŒãã«ã®ã¢ã«ãã¬ã³åäœã«ãããã
ãããã·åºã¯ãäŸãã°é ¢é žã®ãããªèèªæã«ã«ã
ã³é žã®ã¢ã·ã«åºã«ããäžéšãŸãã¯å šéšã¢ã·ã«åã
ããŠããŠãããã ãã®çºæã§çšããã«å¥œé©ãªãšãŒãã«ã¯ã芪氎
æ§ã»èŠªæ²¹æ§ææ°ïŒHLBæ°ïŒãçŽ10ãªããçŽ20ã
ç¹ã«çŽ12ãªããçŽ16ã®ãã®ã§ããã ãã®çºæã§çšããã«ç¹ã«å¥œé©ãªãšãŒãã«ã¯ãã
ãªãªãã·ã¢ã«ãã¬ã³éšåã®å¹³åããè¿ãåäœæ°
ïŒäžåŒäžã®ïœïŒãïŒãªãã75ã奜é©ã«ã¯ïŒãªãã
30ãç¹ã«16ãªãã26ã®ãã®ã§ããããšãŒãã«ã¯å ¬
ç¥ã®æ¹æ³ã«ããåŸããããåºç¯å²ã®è£œåãåžè²©ã
ããŠãããäŸãã°ã¢ã¡ã«ã³ãŒã«ç€Ÿããåæšåãœã«
ã©ã³ã§ãè±çç³ãã瀟ãICI瀟ããã³ã¢ãã©ã¹ç€Ÿ
ããåæšåãšãã¬ãã¯ã¹ãããªã€ããã³ã©ãŠã¬ã¹
ã§ãããã³ã¯ããŒã瀟ããåæšåã»ããã¯ããŽã«
ã§æäŸãããŠããã ãã®çºæã§çšããã«é©ããããªãªãã·ã¢ã«ãã¬
ã³ãšãŒãã«ã®äŸã¯æ¬¡ã®éãã§ããã ïŒPOAã¯ããªãªãã·ãšãã¬ã³ãšãŒãã«ãPOP
ã¯ããªãªãã·ãããã¬ã³ãšãŒãã«ãïœã¯POEïŒ
POPéšåã®å¹³åããè¿ãåäœæ°ãè¡šããïŒ ïŒ ã³ã¬ã¹ããªã«ãšãŒãã« 1.1 ãœã«ã©ã³ïŒ£â24âPOEïŒïœïŒ24. ïŒ ã©ããªã³ã¢ã«ã³ãŒã«ã®ãšãŒãã« 2.1 ãœã«ã©ã³16âPOEïŒïœïŒ16. 2.2 ãœã«ã©ã³25âPOEïŒïœïŒ25. 2.3 ãœã«ã©ã³75âPOEïŒïœïŒ75. 2.4 ãœã«ã©ã³PBâ10âPPEïŒïœïŒ10. 2.5ãœã«ã©ã³98âPOEïŒïœïŒ10ïŒéšåã¢ã»ãã«åïŒ 2.6ãœã«ã©ã³97âPOEïŒïœïŒïŒïŒå®å šã¢ã»ãã«åïŒ ïŒ ã©ãŠãªã«ãšãŒãã« 3.1ãšãã¬ãã¯ã¹709ïŒã©ãŠã¬ã¹ ïŒâPOEïŒïœïŒ
9. 3.2 ã©ãŠã¬ã¹ïŒïŒããªã€30âPOEïŒïŒžïŒ4. 3.3 ã©ãŠã¬ã¹23ïŒããªã€35âPOEïŒïœïŒ23. ïŒ ã»ãã«ãšãŒãã« 4.1 ã»ããã¯ããŽã«âPOEïŒïœïŒ20ãªãã24. ã©ããªã³ã¢ã«ã³ãŒã«ã¯ãçŸæ¯èã¢ã«ã³ãŒã«ãšã
ãŠãç¥ãããŠãããã³ã¬ã¹ãããŒã«ããžãããã³
ã¬ã¹ãããŒã«ããã³ã©ãã¹ãããŒã«ã®æ··åçã§ã
ãã ãã®çºæã§çšããã«å¥œé©ãªãšãŒãã«ã¯ãããªãª
ãã·ãšãã¬ã³ã³ã¬ã¹ããªã«ãšãŒãã«ãããªãã¡äž
åŒïŒïŒã«ãããŠïœïŒïŒã§ROãã³ã¬ã¹ãããŒã«
æ®åºã®ãã®ãç¹ã«ããªãªãã·ãšãã¬ã³éšåã®ãã
è¿ãåäœæ°ã16ãªãã26ãæã奜ãŸããã¯çŽ24ã®
ãšãŒãã«ã§ããã ããã«ããã®ãããªãšãŒãã«ã¯æ±æç©è³ªç¹ã«ä»
ã®ããªãªãã·ã¢ã«ãã¬ã³ãšãŒãã«ãå«ãŸãªãããš
ãæãŸãããæãæãŸããã®ã¯ãçŽããªãªãã·ãš
ãã¬ã³ã³ã¬ã¹ããªã«ãšãŒãã«ãå°ãªããšã75ïŒ ã
ãã奜ãŸããã¯å°ãªããšã85ïŒ ãæã奜ãŸããã¯
å°ãªããšã90ïŒ ïŒééïŒå«ãŸããããšã§ããã çé¢æŽ»æ§å€ãäŸãã°ããªãªãã·ã¢ã«ãã¬ã³ãšãŒ
ãã«ãçšããããå Žåããã®çºæã®çµæç©äžã«å
åšããéã¯åã ã®äœ¿çšçé¢æŽ»æ§å€ãåã ã®æäžæ¹
æ³ïŒäŸãã°ç¹æ¶²ãŸãã¯ã¹ãã¬ã€ïŒããã³ææã®å¹
æã«ããç°ãªãããããäžè¬ã«ãååšéã¯çŽ2.0
ããçŽ200mgïŒmlãŸã§ïŒå¥œãŸããã¯çŽ100mgïŒmlãŸ
ã§ãããã«å¥œãŸããã¯çŽ20mgïŒmlãŸã§ïŒã奜é©ã«
ã¯çŽïŒããçŽ30mgïŒmlãŸã§ïŒå¥œãŸããã¯çŽ15mgïŒ
mlãŸã§ïŒãæã奜ãŸããã¯çŽ10mgïŒmlã§ããã ãã®çºæã®æ¹æ³ã«ãããã€ãŠæäžããã«ã«ã·ã
ãã³ã®éãããªãã¡çµæç©äžã®æå¹æåã®éã¯ã
å¿è«åã ã®äœ¿çšã«ã«ã·ããã³ãæ²»çæ¡ä»¶ãææã®
æäžé »åºŠããã³ææã®å¹æã«ããç°ãªãã äžèšå®æœäŸïŒã瀺ãããã«ããã®çºæã®æ瀺ã«
ãã錻å æäžã§åŸãããè¡æŒ¿äžæ¿åºŠãšããŠæž¬å®ã
ãããã«ã«ã·ããã³ç¹ã«ãµãŒã¢ã³ã«ã«ã·ããã³ã®
çäœå å©çšæ§ã¯ãéåžžçèå 泚å°ã§åŸãããå€ã®
çŽ50ïŒ ãªãŒããŒãšããé©ãã¹ãé«ãã§ããããšã
å€æããããããã€ãŠããã®çºæã«ããæäžã¯ã
äœå£å ãäŸãã°çèå æäžã«ããæ²»çã«èŠããçš
éã®ã»ãŒïŒÃãŸãã¯ãã以äžãäŸãã°çŽïŒãªãã
ïŒÃã®ãªãŒããŒã®çšéãäžããããã«ããŠè¡ãªã
ããã åŸæ¥ãã«ã«ã·ããã³ãäŸãã°ãµãŒã¢ã³ã«ã«ã·ã
ãã³ã«ããæ²»çãçèå 泚å°ã«ããè¡ãªãå Žåã
çŽ50ãªãã100MRCåäœã®åå¥çšéãçŽïŒÃïŒæ¥
ãªããçŽïŒÃïŒé±ã®å²åã§é©çšãããããããã€
ãŠããã®çºæã«ãã錻å æäžã§ã¯ãçŽ50ãªãã
400MRCåäœãããã«å¥œãŸããã¯çŽ100ãªããçŽ
200MRCåäœã®çšéãçŽïŒÃïŒæ¥ãªããçŽïŒÃïŒ
é±ã®é »åºŠã§æäžããŠæ²»çããã®ãé©åœã§ãããäž
èšçšéã¯ïŒåã®é©çšã§æäžããããšãããªãã¡çŽ
50ãªããçŽ400MRCåäœã奜ãŸããã¯çŽ100ãªã
ãçŽ200MRCåäœã®ã«ã«ã·ããã³ãããªãïŒå錻
å çšéã®æäžã§æ²»çãè¡ãªãã®ã䟿å©ã§ãããå¥
ã®æ¹æ³ãšããŠãäžèšçšéãïŒæ¥ã«ééã眮ããŠè¡
ãªãäŸãã°ïŒãªããïŒåã®é©çšã«åå²ããåé©çš
ã®çšéãçŽ10ãªããçŽ200ã奜ãŸããã¯çŽ25ãªã
ãçŽ10OMRCåäœãšããããšãã§ããã å錻å é©çšã§æäžããå šçµæç©éã¯ãçŽ0.05ãª
ãã0.15mlã代衚çã«ã¯çŽ0.1mlãäŸãã°0.09mlã
é©åœã§ããããããã€ãŠããã®çºæã§çšããçµæ
ç©ã¯ãmlåœãçŽ150ãªããçŽ8000ã奜ãŸããã¯çŽ
500ãªããçŽ4000ãããã«å¥œãŸããã¯çŽ500ãªãã
çŽ2500ãæã奜ãŸããã¯çŽ1000ãªããçŽ
2000MRCåäœã®ã«ã«ã·ããã³ãäŸãã°ãµãŒã¢ã³
ã«ã«ã·ããã³ãå«ãã®ãé©åœã§ããã 錻å æäžã®ããã«ããã®çºæã®çµæç©ã¯ãå«æ
çµæç©ã錻ç²èã«é©çšãåŸãæ段ãåãã容åšã
äŸãã°éŒ»çšã¢ããªã±ãŒã¿ãŒè£ 眮å ã«å ¥ããã®ãé©
åœã§ãããé©åœãªã¢ããªã±ãŒã¿ãŒã¯åœè©²æè¡åé
ã§å ¬ç¥ã§ããã液äœçµæç©ãç¹æ¶²ãŸãã¯ã¹ãã¬ã€
ã®åœ¢ã§éŒ»ç²èã«æäžããã«é©ãããã®ã§ãããã«
ã«ã·ããã³ã®çšéã¯ã§ããã ãæ£ç¢ºã«å¶åŸ¡ããã¹
ãã§ãããããæäžéã®ç²Ÿå¯ãªèª¿ç¯ãå¯èœãªã¹ã
ã¬ã€ã¢ããªã±ãŒã¿ãŒã®äœ¿çšãäžè¬ã«å¥œãŸãããé©
åœãªæäžè£ 眮ã«ã¯ãäŸãã°åŽé§è£ 眮ãäŸãã°ãã³
ãåŽé§åšããã³ãšã¢ããŸã«ãã€ã¹ãã³ã¶ãŒãå«ãŸ
ãããåŸè ã®å Žåãã¢ããªã±ãŒã¿ãŒã¯ãã®çºæã®
çµæç©ãšå ±ã«éŒ»çšã¢ããªã±ãŒã¿ãŒã§äœ¿çšããã«é©
ããæšé²å€ïŒãããã©ã³ãïŒãå«ããåŽé§è£ 眮ã¯
å«æçµæç©ã錻ç²èã«æŸåºã§ããé©åœãªã¹ãã¬ã€
ã¢ããã¿ãŒãåããŠããããã®ãããªè£ 眮ã¯åœæ¥
è ã«åšç¥ã§ããã 容åšãäŸãã°éŒ»çšã¢ããªã±ãŒã¿ãŒã¯ãïŒåã®éŒ»
å æäžçšéãŸãã¯äŸãã°æ°æ¥ãŸãã¯æ°é±éã«ãã
ã€ãŠäŸçµŠããæ°åã®é£ç¶çšéã«å åãªéã®çµæç©
ãå«ãããšãã§ãããåäŸçµŠçšéã¯åè¿°ããéã§
ããã®ã奜ãŸããã ãããã€ãŠããã®çºæã¯ããã« A.ïŒïŒ ã«ã«ã·ããã³ãããã³ () å¡©åãã³ã¶ã«ã³ããŠã ãã () 錻ç²èã«é©çšããã«é©ãã液äœåžéå€ãŸ
ãã¯æ äœäžã«å«ãŸããŠãªãã 錻å æäžçšå»è¬çµæç©ãå«ã容åšã«ãããŠãäž
èšå®¹åšã¯å«æçµæç©ã奜ãŸããã¯ã¹ãã¬ã€ã®åœ¢ã§
錻ç²èã«é©çšãåŸãæ段ãåããã容åšã  ã«ã«ã·ããã³ã«ããåŠçœ®ãå¿ èŠãšãã察象ã«
ã«ã«ã·ããã³ãæäžããæ¹æ³ã«ãããŠãäžèšæ¹
æ³ããäžèšïŒ¡ã«èšèŒããïŒïŒïŒïŒããã³
ïŒïŒãããªãçµæç©ãäžèšå¯Ÿè±¡ã«çµéŒ»ã«ãŒã
ã§æäžããããšãããªããæ¹æ³ã ãæäŸãããã®ã§ããã äžèšïŒ¡ã«å®çŸ©ãã容åšïŒã¢ããªã±ãŒã¿ãŒã¯ã錻
çšãšã¢ããŸã«ã¢ããªã±ãŒã¿ãŒã§ããã®ã奜ãŸã
ãã奜é©ãªã®ã¯ãçŽ0.05ãªããçŽ0.15mlãäŸãã°
çŽ0.1mlã®å«æçµæç©ååå®éã®é©çšãå¯èœãªã
ã®ã§ããã äžèšïŒ¡ããã³ïŒ¢ã«å®çŸ©ãã容åšïŒã¢ããªã±ãŒã¿
ãŒè£ 眮ïŒæ¹æ³ã§çšããé©åœãªçµæç©ããã³åæå
ïŒïŒãïŒïŒãïŒïŒã¯ãåè¿°ãããã®ã§ãããã
ã®çºæã®æ¹æ³ã«ãããé©åœãªæäžæ³ããåè¿°ãã
éãã§ããã ããã«ããã®çºæã¯ã () ã«ã«ã·ããã³ãããã³ () å¡©åãã³ã¶ã«ã³ããŠã ãã () 錻ç²èã«é©çšããã«é©ãã液äœåžéå€ãŸã
ã¯æ äœäžã«å«ãŸããŠãªãã 錻å æäžçšæ¶²äœå»è¬çµæç©ã®è£œé æ³ã«ãããŠã
æåïŒïŒãšæåïŒïŒãå質混åç©ãäŸãã°æ
åïŒïŒäžæº¶æ¶²ãšããå¿ èŠã«å¿ããŠåŸãããçµæ
ç©ã錻ç²èã«é©çšãåŸãæ段ã奜é©ã«ã¯åŸããã
çµæç©ãã¹ãã¬ã€ã®åœ¢ã§éŒ»ç²èã«é©çšãåŸãæ段
ãåãã容åšå ã«å°å ¥ããããšãããªããæ¹æ³ ãæäŸãããã®ã§ããã ãã®çºæã®çµæç©ã®å®å®æ§ã¯åžžæ³ã«ãã枬å®ã
ãããšãã§ããã äžæŽ»æ§çªçŽ é°å²æ°äžã®ãã®çºæã®çµæç©ã®ã«ã«
ã·ããã³å«éã¯ãæšæºåæè©Šéšã«ãããšã20âã§
ïŒå¹Žéã«å解ããã®ã10ïŒ ä»¥äžã§ããã äŸãã°ãåŸèšå®æœäŸïŒã®éŒ»çšã¹ãã¬ã€çµæç©ã
ã¬ã©ã¹å®¹åšäžçªçŽ é°å²æ°äžã«ïŒâã20âããã³30
âã§ïŒã«æé貯èµãããïŒâããã³20âã§ã¯æ€åº
å¯èœïŒïŒïŒ 以äžïŒãªã«ã«ã·ããã³ã®å解ãèªãã
ããªãã€ãã30âã§ã¯ïŒïŒ ã®å解ãèªãããã
ããããã¯çŽæ°Žæº¶æ¶²ã§äºæãããå€ããå°ããã
ãã®çµæã¯ãé©åœãªå®å®æ§ãããªãã¡å¯å°ãã容
åšäžçªçŽ é°å²æ°äžã§ïŒå¹Žæ ¹ã«å解ã10ïŒ ä»¥äžã§ã
ãããšã瀺ãã ãŸããã®çºæã®å¡©åãã³ã¶ã«ã³ããŠã ãå«ãçµ
æç©ã¯ãäŸãã°æšæºè©ŠéšãäŸãã°ã¢ãŒãã³çã
Zbl.Bakt.Hyg.I.Abt.Orig.B.1972ã478â484é
ïŒ1981幎ïŒããã³ã¢ãŒãã³ãActa.Pharm.
Technol.22å·»247â253é ïŒ1976幎ïŒèšèŒã®æ¹æ³
ã«ãããšã埮çç©ã«ããæ±æã«ãå®å®ã§ãããäŸ
ãã°ãæšæºè©Šéšã«ãããšãçµæç©ã«æšæºçŽ°èããª
ãã¡ãšã·ãšãªãã¢ã»ã³ãªATCC8789ãã·ãŠãŒãã¢
ãã¹ã»ãšã«ã®ããŒã¶ATCC9027ãã¹ã¿ããã³ãã«
ã¹ã»ãªãŠã¬ãŠã¹ATCC6538ãã¹ãã¬ããã³ãã«
ã¹ã»ããªã²ãã¹ATCC8668ãããã³æšæºçèããª
ãã¡ã«ã³ãžãã»ã¢ã«ãã«ã³ã¹ATCC10231ããµã
ã«ããã»ã¹ã»ã»ã¬ããµãšATCC9763ãã¢ã¹ãã«ã®
ã«ã¹ã»ãã²ã«ATCC16404ããã³ããã·ãªãŠã ã»
ã¹ãããATCC10499ãæ¥çš®åŸ24æé以å ã«ãè
æ°ã¯0.1ïŒ ãŸãã¯ãã以äžã«æžå°ããã å®å®æ§è©Šéšã§ã¯ãåŸèšå®æœäŸïŒã®éŒ»çšã¹ãã¬ã€
çµæç©ãã¬ã©ã¹å®¹åšäžçªçŽ é°å²æ°äžã«30âã§ïŒã«
æ貯èµãããã·ãŠãŒãã¢ãã¹ã»ãšã«ã®ããŒã¶
ATCC9027ãã¹ã¿ãã€ãã³ãã«ã¹ã»ãªãŠã¬ãŠã¹
ATCC6538ãã¹ãã¬ããã³ãã«ã¹ã»ããªã²ãã¹
ATCC8668ããã³çèã®ã«ã³ãžãã»ã¢ã«ãã«ã³ã¹
ATCC10231ããµãã«ããã»ã¹ã»ã»ã¬ããµãš
ATCC9763ãã¢ã¹ãã«ã®ã«ã¹ã»ãã²ã«
ATCC16404ããã³ããã·ãªãŠã ã»ã¹ããã
ATCC10499ãå ããŠæ¥çš®æ¶²äžã®èæ°ãçŽïŒÃ105
åã«ãããïŒæé以å ã«ãèæ°ã¯0.1ïŒ ä»¥äžã«æž
å°ãããïŒé±é以å ã«ãèãèªããããªããªã€
ãã ããã«ãæšæºè©Šéšã«ãããšããã®çºæã®çµæç©
ã¯å¿å®¹æ§ããããäŸãã°ã·ãŠãã³ã¹çãActa
Otolaryng.70å·»26â27é ïŒ1970幎ïŒã®ãã€ã¯ãã
ãªããªã·ãã°ã©ãæ³ã«ãããšãæäžåŸ20åãŸã§çŽ°
æ¯æ¯ååæ°ã®æå¶ã¯50ïŒ ä»¥äžã§ãã€ãã æšæºèšåºè©Šéšã§ãåºãæèŠã¯ã»ãšãã©ãŸãã¯å š
ããªãã䜿çšäžæ±æã«å¯ŸããŠè¯å¥œãªå®å®æ§ã瀺ã
ãã 以äžãå®æœäŸã«ãããã®çºæã説æããã å®æœäŸ ïŒ éŒ»å æäžã«é©ãããµãŒã¢ã³ã«ã«ã·ããã³å«æçµ
æç©ã®è£œé ã æ å éïŒml (1) ãµãŒã¢ã³ã«ã«ã·ããã³ïŒæå¹æåïŒ10ïŒ
0.1375mg éå° 0.01375mg èš 0.15125mg (2) NaCl 7.5mg (3) å¡©åãã³ã¶ã«ã³ããŠã 0.1mg (4) HClïŒINïŒ å ããŠPH3.7ã«ãã (5) èžçæ°Ž æçµå®¹é1.0mlã«ãã æåïŒãªããïŒãçªçŽ ã¬ã¹äžã§åžžæ³ã«ããïŒæ
çµå®¹é2500mlãåŸãä»èŸŒéã§ïŒãµãŒã¢ã³ã«ã«ã·ã
ãã³10ïŒ ãéæ倱ãè£ãããã«å ããŠåãã
ãã次ãã§ïŒãå ããŠPH3.7ã«ããèžçæ°Žãå ã
ãŠæçµå®¹é2500mlã«ãããåŸããã溶液ãé
ïŒäŸãã°0.2ÎŒïœãã€ã«ã¿ãŒäœ¿çšïŒãã錻å é©çšã
ãã³æº¶æ¶²ïŒmlçšéŒ»çšã¹ãã¬ã€ãã€ã¹ãã³ãµãŒå å¡«
ã«é©ããçµæç©ãåŸãããã®çµæç©ã¯ãçŽ
550MRCåäœã®æå¹æåïŒmlãå«ã¿ãã¢ããªã±ãŒ
ã¿ãŒã¯ïŒåäœåœã55åäœãå«ãå®éãæŸåºããã å®æœäŸ ïŒ çžå¯Ÿççäœå å©çšæ§å®éšããµãŒã¢ã³ã«ã«ã·ãã
ã³ã®éŒ»å é©çšïŒçèå 泚å°ã äœé50ãªãã85Kgã®ç·æ§ïŒåã女æ§ïŒåãããª
ã12åã®å¿é¡è ã«ããè©Šéšãè¡ãªã€ããå被æ€è
ã¯ã«ã«ã·ããã³ã®ïŒåæäžãããªãã¡çèå æäž
ïŒåãšéŒ»å æäžïŒåãåãããæäžã¯äžèšçšéã§
è¡ãªã€ãã A.錻å A1.55MRCåäœ A2.110MRCåäœ A3.220MRCåäœ B.çèå 50MRCåäœ éŒ»å æäžã¯ãå®æœäŸïŒã®çµæç©ãšãåã¹ãã¬ã€
çšéåœã55MRCåäœãæŸåºããã¹ãã¬ã€ã¢ããª
ã±ãŒã¿ãŒãçšããŠè¡ãªã€ããæäžã®ããã«ã被æ€
è ã¯é éšãåŸæ¹ã«åŸããŠèäœã§ïŒåé暪ããã€
ããæäžçŽåã«éŒ»ãããã§éŒ»åãæž æããã çèå 泚å°ã¯ãå¡©åãã³ã¶ã«ã³ããŠã ãé€ãã
å€ã¯å®æœäŸïŒãšåæ§ãª50MRCåäœå«æçµæç©ïŒ
mlã®ïŒåçšéããäžæ®¿çã«æ³šå°ããŠè¡ãªã€ãã å被æ€è ã¯ïŒåã®æäžãç¡äœçºã®é åºã«åãã
åæäžã®éã«å°ãªããšãïŒæ¥éã®ééããããã
åæäžã¯ãæã®ãã«ã¯ããã¿ãŒãããŒãºããé€ã
ã軜ãæé£åŸã«è¡ãªã€ããå°¿ææ³ãä¿ã€ããã«ã
åŠçœ®åŸïŒæéæ¯ã«æ°ŽãŸãã¯ãªã¬ã³ãžãžãŠãŒã¹100
mlãäžãããåŠçœ®åŸïŒæéããããŠããé£ç©ãäž
ããã è¡æ¶²è©Šæã¯ãæäžçŽåïŒå¯Ÿç §ïŒããã³æäžåŸ
ïŒã15ã30ã60ã90ã120ã180ã240ã360ããã³
480åã«æ¡åãããå¯Ÿç §ã«ã¯20mlã以äžã®è©Šæã«
ã¯ïŒmlãæ¡åããã åè¡æž ãµã³ãã«äžã®ãµãŒã¢ã³ã«ã«ã·ããã³æ¿åºŠ
ã¯ãã©ãžãªã€ã ãã¢ãã»ã€ã«ãã枬å®ãããè©Šéš
äžã¯è¡å§ãå¶åŸ¡ããå¯äœçšã調ã¹ãããå°¿è©Šéã
æ¡åãããå¯äœçšãäŸãã°æªå¿ãèªããããã ãµãŒã¢ã³ã«ã«ã·ããã³è¡æŒ¿æ¿åºŠã«å¯ŸããAUC
ïŒæ²ç·äžé¢ç©ïŒããïŒåã¯26pïœïŒmlã®æ€åºéç
äžãå«ããŠå šéšã®å€ãçšããïŒåã¯æ€åºéçããŒ
ããšããå€ã®äžã«ãçµ±èšçã«èšç®ãããæé«è¡æŒ¿
æ¿åºŠããã³ãã®éææéã枬å®ããã錻å æäžã®
çžå¯Ÿççäœå å©çšæ§ã¯ã錻å ããã³çèå æäžåŸ
çžå¯ŸççšéâæšæºåAUCïŒ50MRCåäœã«åºã¥ãïŒ
ãã決å®ããã åŸãããçµæããã錻å 110ããã³220MRCå
äœæäžåŸã®AUCå€ãçèå 50MRCåäœæäžåŸã®
AUCå€ã«å¹æµãã錻å 110MRCåäœé©çšåŸïŒæ
éãŸã§ãµãŒã¢ã³ã«ã«ã·ããã³è¡æž ã¬ãã«ãæ€åºé
çå ã«æ®ãã®ã«å¯ŸããŠçèå 50MRCåäœé©çšã§
ã¯ïŒæéã§ããããšãããã€ãã220MRCåäœã®
æé«çšéã§ãã錻å æäžã§ã¯å¯äœçšãèªããããª
ãã€ãã å®æœäŸ ïŒ éŒ»å æäžã«é©ãããµãŒã¢ã³ã«ã«ã·ããã³å«æçµ
æç©ã®è£œé ã çµæç©çªå· 䜿çšãµãŒã¢ã³ã«ã«ã·ããã³é 3a 0.06875mgïŒml 3b 0.275mgïŒml 3c 0.55mgïŒml 3d 1.1mgïŒml çµæç©ã¯ãåéã®æåïŒããã³ïŒïŒãããã7.5
mgãŸãã¯0.1mgïŒmlïŒã䜿çšããæåïŒãçšããŠ
åãPH3.7ã«èª¿ç¯ããæåïŒãçšããŠå¿ èŠãªæçµ
容éã«ããããšã«ãããå®æœäŸïŒãšåæ§ã«è£œé ã
ããåŸãããçµæç©ã¯ãïŒmlåœãçŽ250ïŒçµæç©
3aïŒã1000ïŒ3bïŒã2000ïŒ3cïŒããã³4000ïŒ3dïŒ
MRCåäœã®æå¹æåãå«ã¿ãïŒåäœåœã0.2mlã®
æå¹æåãçµæç©3aã3bã3cããã³3dã«å¯Ÿãã
ããã25ã100ã200ããã³400MRCåäœïŒåäœã
ãæŸåºãã錻çšã¹ãã¬ã€ãã€ã¹ãã³ãµãŒã«å å¡«ã
ããå¿è«ã掻æ§ã®ç°ãªããµãŒã¢ã³ã«ã«ã·ããã³ã
䜿çšããå Žåã«ã¯ãMRCã§èŠå®ããå¿ èŠæ¿åºŠã®
éæã®ããã«ç°ãªã€ãéãå¿ èŠãšããã å®æœäŸ ïŒ éŒ»å æäžã«é©ãããµãŒã¢ã³ã«ã«ã·ããã³ãšéã€
ãªã³çé¢æŽ»æ§å€å«æçµæç©ã®è£œé ã äžèšæåãè¿œå ãã以å€ã¯ãå®æœäŸïŒãšåæ§ã«
ããŠçµæç©ã補é ããã
ãæ°èŠãªïŒã¬ã¬ãã¹ïŒè£œå€çµæç©ã«é¢ãããã®ã§
ããã ã«ã«ã·ããã³é¡ã¯ãçš®ã ã®åšç¥ã®å»è¬çšéã«çš
ãããããå»è¬æŽ»æ§ãæããå ¬ç¥ã®é·éããªãã
ãããå«ãã§ãããäŸãã°ãµãŒã¢ã³ïŒããã»ãŸã
é¡ïŒããã³ããªãã«ã«ã·ããã³ãå«ããŠãçš®ã ã®
ã«ã«ã·ããã³ãåžè²©ãããäŸãã°ããŒãžãšãã
ç ãé«ã«ã«ã·ãŠã è¡çããã³éªšå€åçã®æ²»çã«åº
ãçšããããŠããã ããããããªãããããäžè¬ã«ããã§ãããã
ã«ãã«ã«ã·ããã³é¡ã®å¥œé©ãã€æå¹ãªæäžæ段ã«
ã¯å€ãã®å°é£æ§ãååšãããããªããããã§ãã
ãããã«ã«ã·ããã³ã¯æäžã«éãå解ããæãã
äœæ¶²äžã«ç§»è¡ããã®ãå°é£ã§ããããã®çç±ã
ããæå¹ãªæ²»çãè¡ãªãããã®äžè¬çãªå¯äžã®çµ
è·¯ã¯ãè žç®¡å€æäžã§ãã€ããäžè¬ã«ãæäžæ³ã¯æ³š
å°ã§ãã€ãããã®ãããªæäžæ³ã¯äœã奜ãŸãããª
ããéåžžã®ééã§æäžãè¡ãªã€ãå Žåæ£è ã«èã
ãèŠçãäžããããããã€ãŠãæ£è ã®äžæºãå°ãª
ãã奜ãŸããã¯å®¹æã«èªå·±æäžã§ãåæã«èšåºç
æ²»çã«å åæå¹ãªçäœå å©çšçãéæã§ããå®è¡
å¯èœãªä»£æ¿æ段ããé·å¹Žã®é倧ããªç®æšãšãªã€ãŠ
ããã ãã®çºæè ã¯ãã«ã«ã·ããã³é¡ãçµéŒ»ã«ãŒãã§
æäžããããšãããªãã¡éŒ»ç²èã«é©çšããããšã«
ãããæå¹ãªèšåºçæ²»çãå¯èœãªããšãçºèŠã
ãã詳ããè¿°ã¹ããšããã®çºæè ã¯ããã®çºæã®
ç¹æ®ãªæè¡ã«ãããšãæšæºççè泚å°ã«ããæäž
ã§åŸãããã®ãšåçã®çäœå å©çšæ§ã¬ãã«ããå
åå¿å®¹æ§å ã«ããå®çšççšéã¬ãã«ã®éŒ»å æäžã§
åŸãããããšãç¥ã€ããããã«ãäŸãã°ãµãŒã¢ã³
ã«ã«ã·ããã³ããã³ããªãã«ã«ã·ããã³èªå°äœã
ïŒïŒïŒâAsuâããªãã«ã«ã·ããã³ïŒä»¥äžããšã«
ã«ããã³ãšããïŒãç¹ã«ãµãŒã¢ã³ã«ã«ã·ããã³ãã
ãã®çºæã®æ瀺ã«ããçµéŒ»ã«ãŒãã§æäžããã®ã«
ç¹ã«å¥œé©ã§ããããšãç¥ã€ãã çµéŒ»ã«ãŒãã¯ãäŸãã°éŒ»çšã¢ããªã±ãŒã¿ãŒã«ã
ã錻çšã¹ãã¬ã€ãŸãã¯ç¹æ¶²æäžã«ããæ£è èªèº«ã«
ãã容æã«å®æœã§ãããç°¡åã§èŠçã®å°ãªãæäž
æ³ãæäŸããããã®ã«ãŒãã¯ãäžè¬ã«å»åž«ã®ç£ç£
äžã«è¡ãªãããè žç®¡å€æäžã«èŒã¹ãŠæããã«å€§ã
ãªå©ç¹ãæããã çµéŒ»ã«ãŒãæäžã¯äŸãã°æ³šå°ã®ãããªåŸæ¥äžè¬
ã«è¡ãªãããè žç®¡å€æäžããæããã«æå©ã§ãã
ãã錻çšæäžåœ¢æ ã«çšããçµæç©ã«ã¯æ°å€ãã®é£
ç¹ããããïŒã€ã®åé¡ãç¹ã«ã«ã«ã·ããã³ã®ãã
ãªè€åè¬å€ã®éŒ»å æäžã«ãããŠéèŠãªåé¡ã¯ãäŸ
ãã°ç åæ§ãŸãã¯ä»ã®äžéœåãªåŸ®çç©ã«ããæ±æ
ãé¿ããããã«å åäž¡ç«å¯èœã§æå¹ãªæ段ã®äŸçµŠ
ã§ãããæ±æããã®ä¿è·ã®ããã®æå¹æåãšäž¡ç«
å¯èœã§æå¹ãªé²è å€ã¯ãç¹ã«æ±æã®å±éºæ§ã極ã
ãŠé«ã錻çšå»è¬çµæç©ã«ãããŠæ¥µããŠéèŠã§ã
ããé²è å€ã¯åœåã®æ±æåé¿ãäŸãã°è£œå€äžãã
ã³å®¹åšãžã®çµæç©å å¡«äžã ãã§ãªãã䜿çšäžãç¹
ã«ïŒåã®å®¹åšïŒã¢ããªã±ãŒã¿ãŒããã®å€åæäžã
å¿ èŠãªå Žåã®äœ¿çšäžã«ç¶ãæ±æåé¿ã®ããã«å¿ èŠ
ã§ããããã°ãã°ããã§ããããã«ã錻çšã¢ããª
ã±ãŒã¿ãŒã䜿çšåã«æ°ãæãä¿ç®¡ãããå Žåã«ã
ç¹ã«åé¡ãçããããã®æéã«ãäŸãã°ã¢ããªã±
ãŒã¿ãŒå å£ãžã®åžåãç±å解ããŸãã¯é²è å€ãã
ãçšåºŠé床ã®æ®çºæ§ããã€å Žåãã¢ããªã±ãŒã¿ãŒ
ããã®æŒåºã«ãããéžæããé²è å€ãç¡å¹ã«ãªã
åŸããããã«ãå®éã®äœ¿çšæéã«ãïŒããã³ïŒå
ã®ã¢ããªã±ãŒã¿ãŒããã®å€åæäžãäºå®ããŠãã
å Žåæ°æ¥ãªããæ°é±éã«ãããæéã«ãïŒã¢ããª
ã±ãŒã¿ãŒå ã«äžéœåãªåŸ®çç©ãŸãã¯æ±æç©ãå€æ°
ãŸãã¯éŒ»åããæŒã蟌ã¿ãããã¯æµžå ¥ããããã
ãããããŸããçµæç©ã¯äŸãã°èŒžéãããã¯ä¿ç®¡
äžã«çæéã®é«æž©ã«ãããããããšãããã äžèšã®é£ç¹ã«å ããŠã錻å é©çšã®ããã«éçºã
ãå»è¬çµæç©ã¯åæã«ãç¹ã«çŽæ¥é©çšãããéšäœ
ã«å¯ŸããŠé©åºŠã®å¿å®¹æ§ããããªããã°ãªããªãã
äŸãã°ã錻ç²èãåºæ¿ããŠã¯ãªããïŒäŸãã°åºã
æããäžããŠã¯ãªããïŒã现æ¯ã®æ¯ååæ°ãæžå°
ããŠã¯ãªããªãã ã«ã«ã·ããã³å€çµæç©ã«çšãåŸããã®ãšããŠã
極ããŠå€æ°ã®åšç¥ã®é²è å€ãæåºãããŠãããã
ãããå®éšã®çµæã«ã«ã·ããã³ã®éŒ»çšã¹ãã¬ã€ã«
å®çšããã«ã¯ãã¹ãŠã奜é©ã§ã¯ãªãããšãå€æã
ããäŸãã°ãã«ã«ã·ããã³ã®éŒ»çšã¹ãã¬ã€å€çµæ
ç©äž0.6ïŒ ã®ã¯ãã«ãã¿ããŒã«ã¯ãè©ŠéšèPen.ste
ckiiã«å¯ŸããŠã现èæ°ã0.1ïŒ ä»¥äžã«æžããããš
ãå¿ èŠãªïŒæ¥é以äžã«ããã€ãŠäžå åãªæŽ»æ§ãã
瀺ããªãã€ããããã«ãã¯ãã«ãã¿ããŒã«ã¯ããŽ
ã æ ãšéŒ»çšã¹ãã¬ã€ã¢ããªã±ãŒã¿ãŒã®ã¹ãã¬ã€ã
ã³ããšã³ãã®éã«çšããããä»ã®ãžãšã€ã³ããå·
ããããšãå€æããã ãã®äžã«ãã¯ãã«ãã¿ããŒã«ã¯ãã·ãŠãã³ã¹
çãActa Otolarrng.70å·»16ïŒ28ïŒ1970幎ïŒãã€
ã¯ãããªããªã·ãã°ã©ãæ³ã«ãããšã0.6ïŒ ã«ã
ããŠãã©ããæ°ç®¡ã®ç¹æ¯æ¯ååæ°ã20åéã«50ïŒ
以äžæå¶ãããããã¯ããŸãã«èæ ®ãããã¹ãæ¬
ç¹ã§ããã ãã®çºæã«ãããšãé©ãã¹ãããšã«ãå¡©åãã³
ã¶ã«ã³ããŠã ãå ±æåã§ããé²è å€ãšããŠçšãã
ããšã«ããã錻å é©çšã«å¿ èŠãªé«åºŠã®å®å®æ§ãšå¿
容æ§ãæããäŸãã°éŒ»çšã¹ãã¬ã€ã¢ããªã±ãŒã¿
ãŒãããªãã¡äŸãã°æ°æ¥ãŸãã¯æ°é±éã«ããã€ãŠ
äžé£ã®åå¥çšéã®æŸåºãå¯èœãªã¢ããªã±ãŒã¿ãŒã«
ããå€åæäžã«æ¥µããŠå¥œé©ãªãã«ã«ã·ããã³ãæ
å¹æåãšããå»è¬çµæç©ãåŸãããããšãå€æã
ããé©ãã¹ãããšã«ããŸãå¡©åãã³ã¶ã«ã³ããŠã
ã®äœ¿çšã¯ãé²è å€ãšããŠçšããã«å¿ èŠãªæ¥µããŠäœ
æ¿åºŠã«ãããŠããã«ã«ã·ããã³å«æçµæç©ã®çµéŒ»
åžåç¹æ§ã«æçãªå©ç¹ãããããããããã€ãŠéŒ»
å é©çšã§åŸãããã«ã«ã·ããã³ã®çäœå å©çšæ§ã
å¢åŒ·ããããšãå€æããã ãããã€ãŠããã®çºæã¯ã () ã«ã«ã·ããã³ãããã³ () å¡©åãã³ã¶ã«ã³ããŠã ãã ()錻ç²èã«é©çšããã«é©ãã液äœåžéå€ãŸãã¯
æ äœäžã«å«ãŸããŠãªãã 錻å æäžçšå»è¬çµæç©ãæäŸãããã®ã§ããã ãã®æ现æžã«ãããŠããã«ã«ã·ããã³ãã®èªã¯
åºçŸ©ã§çšãããã®ãšãã倩ç¶ã«ç£ããã«ã«ã·ãã
ã³ã ãã§ãªãããã®å»è¬æŽ»æ§ãæããèªå°äœãã
ã³é¡çžäœãäŸãã°å€©ç¶ã«ç£ãããã®ã«ååšããïŒ
åãŸãã¯ïŒå以äžã®ããããæ®åºã眮æããããŸ
ãã¯ïŒ®âãããã¯ïŒ£æ«ç«¯ã修食ããããã®ãå«ã
ãã®ãšããã ãã®çºæã§çšããã«å¥œé©ãªã«ã«ã·ããã³ã¯ããµ
ãŒã¢ã³ãã²ãšããã³è±ã«ã«ã·ããã³ãããã³ãšã«
ã«ããã³ã§ããããããã®ååç©ã¯äœããåžè²©ã
ããŠãããæç®äžã«ãã®å»è¬ãšããŠã®æ§è³ªãšå ±ã«
詳现ã«èšèŒãããŠããã åèšã®ããã«ããµãŒã¢ã³ã«ã«ã·ããã³ã®éŒ»å é©
çšã«ãããäŸãã°çäœå å©çšæ°Žæºããã³è¡æŒ¿å å
åšæéã«ãããŠã極ããŠè¯å¥œãªçµæãåŸãããã ãããã€ãŠããµãŒã¢ã³ã«ã«ã·ããã³ã¯ãã®çºæ
ã§çšããã«æãé©ããã«ã«ã·ããã³ã§ããã ãã®çºæã§çšããã«ã«ã·ããã³ã¯ãéé¢äœããŸ
ãã¯å»è¬äžèš±å®¹ãããå¡©ããŸãã¯ã³ã³ãã¬ãã¯
ã¹ãäŸãã°å»è¬äžèš±å®¹ãããé žä»å å¡©ã®åœ¢ã®äœã
ã§ãããããã®çºæã§çšããé©åœãªé žä»å å¡©ã«
ã¯ãäŸãã°å¡©é žå¡©ããã³é ¢é žå¡©ãå«ãŸããã å¡©åãã³ã¶ã«ã³ããŠã ã¯ãå ¬ç¥ã®äžè¬åŒC6H5
âCH2âNRïŒCH3ïŒ2ClïŒïŒ²ã¯C8H17ãªããC18H37
ã§ããïŒã§ä»£è¡šãããïŒçŽã¢ã³ã¢ããŠã å¡©ã®æ··å
ç©ã«äžè¬çã«äœ¿çšãããå称ã§ããããã®çºæã®
çµæç©äžå¡©åãã³ã¶ã«ã³ããŠã æåã®å¥œãŸããæ¿
床ã¯ãå šçµæç©äžçŽ0.002ãªãã0.02ïŒ ã代衚ç
ã«ã¯çŽ0.01ïŒ ïŒééïŒå®¹éïŒã§ããã ãã®çºæã«ãããšãäžèšã®çµæç©ã¯éŒ»ç²èã«ç¹
液ãŸãã¯ã¹ãã¬ã€ã®äœãã«ãã€ãŠãé©çšã§ããã
ããããåŸè¿°ã®ããã«ãã¹ãã¬ã€ããªãã¡åŸ®çŽ°å
å²æ»Žã®åœ¢ã§é©çšããã®ãæã奜ãŸããã å¿è«ããã®çºæã®çµæç©ã¯ä»ã®æåãç¹ã«äžé£
ã®å»è¬äžèš±å®¹ãããåžžçšçé¢æŽ»æ§å€ã«å±ããæå
ãå«ãããšãã§ããã ãã®çºæã®çµæç©ã§çšãã液äœåžéå€ãŸãã¯æ
äœïŒïŒã¯æ°ŽïŒè£œå€çšïŒãããªãã®ã奜ãŸããã
æã奜ãŸããã®ã¯ãé£å¡©æ°Žã§ããããã®çºæã®çµ
æç©ã¯ãçµéŒ»ã«ãŒãã§æäžã§ããããã«è£œå€ãã
ãããã®ç®çã®ããã«ããã®çµæç©ã¯äŸãã°æå°
éã®ææã«ããå¥ã®æåãŸãã¯è³Šåœ¢å€ãäŸãã°å¥
ã®é²è å€ãŸãã¯äŸãã°ã«ããšã€ã³ã®ãããªçŽ°æ¯åº
æ¿å€ãå«ãããšãã§ãããäžè¬ã«éŒ»å é©çšã«ã¯åŒ±
é žæ§PHã奜ãŸããããã®çºæã®çµæç©ã¯çŽïŒãªã
ãïŒã®PHããã€ã®ã奜ãŸãããçŽ3.5ãªããçŽ4.5
ã®PHãæã奜ãŸãããPHã®èª¿ç¯ã¯ãé©åœãªé žãäŸ
ãã°å¡©é žãå ããŠè¡ãªãããšãã§ããã ãã®çºæã®çµæç©ã¯ãŸããé©åœãªç匵æ§ããã³
ç²åºŠããã€ããšãå¿ èŠãšããããã®çµæç©ã¯ãçŽ
260ãªããçŽ380ïœOsïœïŒãªããã«ã®æ»²éå§ãã
ã€ã®ã奜ãŸããããã®çºæã®çµæç©ã«ãããææ
ã®ç²åºŠã¯ãåã ã®æäžåœ¢æ ãäŸãã°æäžãç¹éŒ»æ¶²
ã§ããã錻å çšã¹ãã¬ã€ã§ãããã«ãã€ãŠç°ãª
ããç¹éŒ»æ¶²ã§ã¯ãé©åœãªç²åºŠã¯çŽïŒãªããçŽ40Ã
10-3PaSã§ããã錻å çšã¹ãã¬ã€ã§ã¯ãç²åºŠã¯ïŒ
Ã10-3PaS以äžãäŸãã°ïŒãªããïŒÃ10-3PaSã
é©åœã§ããã ãã®çºæã®çµæç©ãåžžçšã®çé¢æŽ»æ§å€ãå«ãå Ž
åéã€ãªã³çé¢æŽ»æ§å€ã奜ãŸãããç¹ã«å¥œãŸãã
çé¢æŽ»æ§å€ã¯ãäŸãã°äžè¬åŒïŒïŒ ROãâïŒCH2ïŒoâãâx ïŒïŒ ïŒåŒäžãROã¯é«çŽã¢ã«ã³ãŒã«ãç¹ã«ã©ãŠãªã«ãŸ
ãã¯ã»ãã«ã¢ã«ã³ãŒã«ã®ãããªé«çŽã¢ã«ã«ããŒã«
ãŸãã¯ã¢ã«ãã«ããšããŒã«ã®æ®åºããŸãã¯ã¹ãã
ãŒã«æ®åºãç¹ã«ã©ãã¹ãããŒã«ããžãããã³ã¬ã¹
ãããŒã«ãŸãã¯ã³ã¬ã¹ãããŒã«æ®åºã§ããïŒ ã§ç€ºãããããªãªãã·ã¢ã«ãã¬ã³é«çŽã¢ã«ã³ãŒã«
ãšãŒãã«ã䞊ã³ã«ãã®ãããªãšãŒãã«ã®ïŒçš®ä»¥äž
ã®æ··åç©ã§ããããã®çºæã§çšããã«å¥œé©ãªããª
ãªãã·ã¢ã«ãã¬ã³ãšãŒãã«ã¯ãããªãªãã·ãšãã¬
ã³ããã³ããªãªãã·ãããã¬ã³ãšãŒãã«ïŒããªã
ã¡äžåŒäžïœãïŒãŸãã¯ïŒïŒãç¹ã«ããªãªãã·ãšã
ã¬ã³ããã³ããªãªãã·ãããã¬ã³ã©ãŠãªã«ãã»ã
ã«ãããã³ã³ã¬ã¹ããªã«ãšãŒãã«ã䞊ã³ã«ãã®ã
ããªãšãŒãã«ã®ïŒçš®ä»¥äžã®æ··åç©ã§ããã ãããã®ãšãŒãã«ã®ã¢ã«ãã¬ã³åäœã«ãããã
ãããã·åºã¯ãäŸãã°é ¢é žã®ãããªèèªæã«ã«ã
ã³é žã®ã¢ã·ã«åºã«ããäžéšãŸãã¯å šéšã¢ã·ã«åã
ããŠããŠãããã ãã®çºæã§çšããã«å¥œé©ãªãšãŒãã«ã¯ã芪氎
æ§ã»èŠªæ²¹æ§ææ°ïŒHLBæ°ïŒãçŽ10ãªããçŽ20ã
ç¹ã«çŽ12ãªããçŽ16ã®ãã®ã§ããã ãã®çºæã§çšããã«ç¹ã«å¥œé©ãªãšãŒãã«ã¯ãã
ãªãªãã·ã¢ã«ãã¬ã³éšåã®å¹³åããè¿ãåäœæ°
ïŒäžåŒäžã®ïœïŒãïŒãªãã75ã奜é©ã«ã¯ïŒãªãã
30ãç¹ã«16ãªãã26ã®ãã®ã§ããããšãŒãã«ã¯å ¬
ç¥ã®æ¹æ³ã«ããåŸããããåºç¯å²ã®è£œåãåžè²©ã
ããŠãããäŸãã°ã¢ã¡ã«ã³ãŒã«ç€Ÿããåæšåãœã«
ã©ã³ã§ãè±çç³ãã瀟ãICI瀟ããã³ã¢ãã©ã¹ç€Ÿ
ããåæšåãšãã¬ãã¯ã¹ãããªã€ããã³ã©ãŠã¬ã¹
ã§ãããã³ã¯ããŒã瀟ããåæšåã»ããã¯ããŽã«
ã§æäŸãããŠããã ãã®çºæã§çšããã«é©ããããªãªãã·ã¢ã«ãã¬
ã³ãšãŒãã«ã®äŸã¯æ¬¡ã®éãã§ããã ïŒPOAã¯ããªãªãã·ãšãã¬ã³ãšãŒãã«ãPOP
ã¯ããªãªãã·ãããã¬ã³ãšãŒãã«ãïœã¯POEïŒ
POPéšåã®å¹³åããè¿ãåäœæ°ãè¡šããïŒ ïŒ ã³ã¬ã¹ããªã«ãšãŒãã« 1.1 ãœã«ã©ã³ïŒ£â24âPOEïŒïœïŒ24. ïŒ ã©ããªã³ã¢ã«ã³ãŒã«ã®ãšãŒãã« 2.1 ãœã«ã©ã³16âPOEïŒïœïŒ16. 2.2 ãœã«ã©ã³25âPOEïŒïœïŒ25. 2.3 ãœã«ã©ã³75âPOEïŒïœïŒ75. 2.4 ãœã«ã©ã³PBâ10âPPEïŒïœïŒ10. 2.5ãœã«ã©ã³98âPOEïŒïœïŒ10ïŒéšåã¢ã»ãã«åïŒ 2.6ãœã«ã©ã³97âPOEïŒïœïŒïŒïŒå®å šã¢ã»ãã«åïŒ ïŒ ã©ãŠãªã«ãšãŒãã« 3.1ãšãã¬ãã¯ã¹709ïŒã©ãŠã¬ã¹ ïŒâPOEïŒïœïŒ
9. 3.2 ã©ãŠã¬ã¹ïŒïŒããªã€30âPOEïŒïŒžïŒ4. 3.3 ã©ãŠã¬ã¹23ïŒããªã€35âPOEïŒïœïŒ23. ïŒ ã»ãã«ãšãŒãã« 4.1 ã»ããã¯ããŽã«âPOEïŒïœïŒ20ãªãã24. ã©ããªã³ã¢ã«ã³ãŒã«ã¯ãçŸæ¯èã¢ã«ã³ãŒã«ãšã
ãŠãç¥ãããŠãããã³ã¬ã¹ãããŒã«ããžãããã³
ã¬ã¹ãããŒã«ããã³ã©ãã¹ãããŒã«ã®æ··åçã§ã
ãã ãã®çºæã§çšããã«å¥œé©ãªãšãŒãã«ã¯ãããªãª
ãã·ãšãã¬ã³ã³ã¬ã¹ããªã«ãšãŒãã«ãããªãã¡äž
åŒïŒïŒã«ãããŠïœïŒïŒã§ROãã³ã¬ã¹ãããŒã«
æ®åºã®ãã®ãç¹ã«ããªãªãã·ãšãã¬ã³éšåã®ãã
è¿ãåäœæ°ã16ãªãã26ãæã奜ãŸããã¯çŽ24ã®
ãšãŒãã«ã§ããã ããã«ããã®ãããªãšãŒãã«ã¯æ±æç©è³ªç¹ã«ä»
ã®ããªãªãã·ã¢ã«ãã¬ã³ãšãŒãã«ãå«ãŸãªãããš
ãæãŸãããæãæãŸããã®ã¯ãçŽããªãªãã·ãš
ãã¬ã³ã³ã¬ã¹ããªã«ãšãŒãã«ãå°ãªããšã75ïŒ ã
ãã奜ãŸããã¯å°ãªããšã85ïŒ ãæã奜ãŸããã¯
å°ãªããšã90ïŒ ïŒééïŒå«ãŸããããšã§ããã çé¢æŽ»æ§å€ãäŸãã°ããªãªãã·ã¢ã«ãã¬ã³ãšãŒ
ãã«ãçšããããå Žåããã®çºæã®çµæç©äžã«å
åšããéã¯åã ã®äœ¿çšçé¢æŽ»æ§å€ãåã ã®æäžæ¹
æ³ïŒäŸãã°ç¹æ¶²ãŸãã¯ã¹ãã¬ã€ïŒããã³ææã®å¹
æã«ããç°ãªãããããäžè¬ã«ãååšéã¯çŽ2.0
ããçŽ200mgïŒmlãŸã§ïŒå¥œãŸããã¯çŽ100mgïŒmlãŸ
ã§ãããã«å¥œãŸããã¯çŽ20mgïŒmlãŸã§ïŒã奜é©ã«
ã¯çŽïŒããçŽ30mgïŒmlãŸã§ïŒå¥œãŸããã¯çŽ15mgïŒ
mlãŸã§ïŒãæã奜ãŸããã¯çŽ10mgïŒmlã§ããã ãã®çºæã®æ¹æ³ã«ãããã€ãŠæäžããã«ã«ã·ã
ãã³ã®éãããªãã¡çµæç©äžã®æå¹æåã®éã¯ã
å¿è«åã ã®äœ¿çšã«ã«ã·ããã³ãæ²»çæ¡ä»¶ãææã®
æäžé »åºŠããã³ææã®å¹æã«ããç°ãªãã äžèšå®æœäŸïŒã瀺ãããã«ããã®çºæã®æ瀺ã«
ãã錻å æäžã§åŸãããè¡æŒ¿äžæ¿åºŠãšããŠæž¬å®ã
ãããã«ã«ã·ããã³ç¹ã«ãµãŒã¢ã³ã«ã«ã·ããã³ã®
çäœå å©çšæ§ã¯ãéåžžçèå 泚å°ã§åŸãããå€ã®
çŽ50ïŒ ãªãŒããŒãšããé©ãã¹ãé«ãã§ããããšã
å€æããããããã€ãŠããã®çºæã«ããæäžã¯ã
äœå£å ãäŸãã°çèå æäžã«ããæ²»çã«èŠããçš
éã®ã»ãŒïŒÃãŸãã¯ãã以äžãäŸãã°çŽïŒãªãã
ïŒÃã®ãªãŒããŒã®çšéãäžããããã«ããŠè¡ãªã
ããã åŸæ¥ãã«ã«ã·ããã³ãäŸãã°ãµãŒã¢ã³ã«ã«ã·ã
ãã³ã«ããæ²»çãçèå 泚å°ã«ããè¡ãªãå Žåã
çŽ50ãªãã100MRCåäœã®åå¥çšéãçŽïŒÃïŒæ¥
ãªããçŽïŒÃïŒé±ã®å²åã§é©çšãããããããã€
ãŠããã®çºæã«ãã錻å æäžã§ã¯ãçŽ50ãªãã
400MRCåäœãããã«å¥œãŸããã¯çŽ100ãªããçŽ
200MRCåäœã®çšéãçŽïŒÃïŒæ¥ãªããçŽïŒÃïŒ
é±ã®é »åºŠã§æäžããŠæ²»çããã®ãé©åœã§ãããäž
èšçšéã¯ïŒåã®é©çšã§æäžããããšãããªãã¡çŽ
50ãªããçŽ400MRCåäœã奜ãŸããã¯çŽ100ãªã
ãçŽ200MRCåäœã®ã«ã«ã·ããã³ãããªãïŒå錻
å çšéã®æäžã§æ²»çãè¡ãªãã®ã䟿å©ã§ãããå¥
ã®æ¹æ³ãšããŠãäžèšçšéãïŒæ¥ã«ééã眮ããŠè¡
ãªãäŸãã°ïŒãªããïŒåã®é©çšã«åå²ããåé©çš
ã®çšéãçŽ10ãªããçŽ200ã奜ãŸããã¯çŽ25ãªã
ãçŽ10OMRCåäœãšããããšãã§ããã å錻å é©çšã§æäžããå šçµæç©éã¯ãçŽ0.05ãª
ãã0.15mlã代衚çã«ã¯çŽ0.1mlãäŸãã°0.09mlã
é©åœã§ããããããã€ãŠããã®çºæã§çšããçµæ
ç©ã¯ãmlåœãçŽ150ãªããçŽ8000ã奜ãŸããã¯çŽ
500ãªããçŽ4000ãããã«å¥œãŸããã¯çŽ500ãªãã
çŽ2500ãæã奜ãŸããã¯çŽ1000ãªããçŽ
2000MRCåäœã®ã«ã«ã·ããã³ãäŸãã°ãµãŒã¢ã³
ã«ã«ã·ããã³ãå«ãã®ãé©åœã§ããã 錻å æäžã®ããã«ããã®çºæã®çµæç©ã¯ãå«æ
çµæç©ã錻ç²èã«é©çšãåŸãæ段ãåãã容åšã
äŸãã°éŒ»çšã¢ããªã±ãŒã¿ãŒè£ 眮å ã«å ¥ããã®ãé©
åœã§ãããé©åœãªã¢ããªã±ãŒã¿ãŒã¯åœè©²æè¡åé
ã§å ¬ç¥ã§ããã液äœçµæç©ãç¹æ¶²ãŸãã¯ã¹ãã¬ã€
ã®åœ¢ã§éŒ»ç²èã«æäžããã«é©ãããã®ã§ãããã«
ã«ã·ããã³ã®çšéã¯ã§ããã ãæ£ç¢ºã«å¶åŸ¡ããã¹
ãã§ãããããæäžéã®ç²Ÿå¯ãªèª¿ç¯ãå¯èœãªã¹ã
ã¬ã€ã¢ããªã±ãŒã¿ãŒã®äœ¿çšãäžè¬ã«å¥œãŸãããé©
åœãªæäžè£ 眮ã«ã¯ãäŸãã°åŽé§è£ 眮ãäŸãã°ãã³
ãåŽé§åšããã³ãšã¢ããŸã«ãã€ã¹ãã³ã¶ãŒãå«ãŸ
ãããåŸè ã®å Žåãã¢ããªã±ãŒã¿ãŒã¯ãã®çºæã®
çµæç©ãšå ±ã«éŒ»çšã¢ããªã±ãŒã¿ãŒã§äœ¿çšããã«é©
ããæšé²å€ïŒãããã©ã³ãïŒãå«ããåŽé§è£ 眮ã¯
å«æçµæç©ã錻ç²èã«æŸåºã§ããé©åœãªã¹ãã¬ã€
ã¢ããã¿ãŒãåããŠããããã®ãããªè£ 眮ã¯åœæ¥
è ã«åšç¥ã§ããã 容åšãäŸãã°éŒ»çšã¢ããªã±ãŒã¿ãŒã¯ãïŒåã®éŒ»
å æäžçšéãŸãã¯äŸãã°æ°æ¥ãŸãã¯æ°é±éã«ãã
ã€ãŠäŸçµŠããæ°åã®é£ç¶çšéã«å åãªéã®çµæç©
ãå«ãããšãã§ãããåäŸçµŠçšéã¯åè¿°ããéã§
ããã®ã奜ãŸããã ãããã€ãŠããã®çºæã¯ããã« A.ïŒïŒ ã«ã«ã·ããã³ãããã³ () å¡©åãã³ã¶ã«ã³ããŠã ãã () 錻ç²èã«é©çšããã«é©ãã液äœåžéå€ãŸ
ãã¯æ äœäžã«å«ãŸããŠãªãã 錻å æäžçšå»è¬çµæç©ãå«ã容åšã«ãããŠãäž
èšå®¹åšã¯å«æçµæç©ã奜ãŸããã¯ã¹ãã¬ã€ã®åœ¢ã§
錻ç²èã«é©çšãåŸãæ段ãåããã容åšã  ã«ã«ã·ããã³ã«ããåŠçœ®ãå¿ èŠãšãã察象ã«
ã«ã«ã·ããã³ãæäžããæ¹æ³ã«ãããŠãäžèšæ¹
æ³ããäžèšïŒ¡ã«èšèŒããïŒïŒïŒïŒããã³
ïŒïŒãããªãçµæç©ãäžèšå¯Ÿè±¡ã«çµéŒ»ã«ãŒã
ã§æäžããããšãããªããæ¹æ³ã ãæäŸãããã®ã§ããã äžèšïŒ¡ã«å®çŸ©ãã容åšïŒã¢ããªã±ãŒã¿ãŒã¯ã錻
çšãšã¢ããŸã«ã¢ããªã±ãŒã¿ãŒã§ããã®ã奜ãŸã
ãã奜é©ãªã®ã¯ãçŽ0.05ãªããçŽ0.15mlãäŸãã°
çŽ0.1mlã®å«æçµæç©ååå®éã®é©çšãå¯èœãªã
ã®ã§ããã äžèšïŒ¡ããã³ïŒ¢ã«å®çŸ©ãã容åšïŒã¢ããªã±ãŒã¿
ãŒè£ 眮ïŒæ¹æ³ã§çšããé©åœãªçµæç©ããã³åæå
ïŒïŒãïŒïŒãïŒïŒã¯ãåè¿°ãããã®ã§ãããã
ã®çºæã®æ¹æ³ã«ãããé©åœãªæäžæ³ããåè¿°ãã
éãã§ããã ããã«ããã®çºæã¯ã () ã«ã«ã·ããã³ãããã³ () å¡©åãã³ã¶ã«ã³ããŠã ãã () 錻ç²èã«é©çšããã«é©ãã液äœåžéå€ãŸã
ã¯æ äœäžã«å«ãŸããŠãªãã 錻å æäžçšæ¶²äœå»è¬çµæç©ã®è£œé æ³ã«ãããŠã
æåïŒïŒãšæåïŒïŒãå質混åç©ãäŸãã°æ
åïŒïŒäžæº¶æ¶²ãšããå¿ èŠã«å¿ããŠåŸãããçµæ
ç©ã錻ç²èã«é©çšãåŸãæ段ã奜é©ã«ã¯åŸããã
çµæç©ãã¹ãã¬ã€ã®åœ¢ã§éŒ»ç²èã«é©çšãåŸãæ段
ãåãã容åšå ã«å°å ¥ããããšãããªããæ¹æ³ ãæäŸãããã®ã§ããã ãã®çºæã®çµæç©ã®å®å®æ§ã¯åžžæ³ã«ãã枬å®ã
ãããšãã§ããã äžæŽ»æ§çªçŽ é°å²æ°äžã®ãã®çºæã®çµæç©ã®ã«ã«
ã·ããã³å«éã¯ãæšæºåæè©Šéšã«ãããšã20âã§
ïŒå¹Žéã«å解ããã®ã10ïŒ ä»¥äžã§ããã äŸãã°ãåŸèšå®æœäŸïŒã®éŒ»çšã¹ãã¬ã€çµæç©ã
ã¬ã©ã¹å®¹åšäžçªçŽ é°å²æ°äžã«ïŒâã20âããã³30
âã§ïŒã«æé貯èµãããïŒâããã³20âã§ã¯æ€åº
å¯èœïŒïŒïŒ 以äžïŒãªã«ã«ã·ããã³ã®å解ãèªãã
ããªãã€ãã30âã§ã¯ïŒïŒ ã®å解ãèªãããã
ããããã¯çŽæ°Žæº¶æ¶²ã§äºæãããå€ããå°ããã
ãã®çµæã¯ãé©åœãªå®å®æ§ãããªãã¡å¯å°ãã容
åšäžçªçŽ é°å²æ°äžã§ïŒå¹Žæ ¹ã«å解ã10ïŒ ä»¥äžã§ã
ãããšã瀺ãã ãŸããã®çºæã®å¡©åãã³ã¶ã«ã³ããŠã ãå«ãçµ
æç©ã¯ãäŸãã°æšæºè©ŠéšãäŸãã°ã¢ãŒãã³çã
Zbl.Bakt.Hyg.I.Abt.Orig.B.1972ã478â484é
ïŒ1981幎ïŒããã³ã¢ãŒãã³ãActa.Pharm.
Technol.22å·»247â253é ïŒ1976幎ïŒèšèŒã®æ¹æ³
ã«ãããšã埮çç©ã«ããæ±æã«ãå®å®ã§ãããäŸ
ãã°ãæšæºè©Šéšã«ãããšãçµæç©ã«æšæºçŽ°èããª
ãã¡ãšã·ãšãªãã¢ã»ã³ãªATCC8789ãã·ãŠãŒãã¢
ãã¹ã»ãšã«ã®ããŒã¶ATCC9027ãã¹ã¿ããã³ãã«
ã¹ã»ãªãŠã¬ãŠã¹ATCC6538ãã¹ãã¬ããã³ãã«
ã¹ã»ããªã²ãã¹ATCC8668ãããã³æšæºçèããª
ãã¡ã«ã³ãžãã»ã¢ã«ãã«ã³ã¹ATCC10231ããµã
ã«ããã»ã¹ã»ã»ã¬ããµãšATCC9763ãã¢ã¹ãã«ã®
ã«ã¹ã»ãã²ã«ATCC16404ããã³ããã·ãªãŠã ã»
ã¹ãããATCC10499ãæ¥çš®åŸ24æé以å ã«ãè
æ°ã¯0.1ïŒ ãŸãã¯ãã以äžã«æžå°ããã å®å®æ§è©Šéšã§ã¯ãåŸèšå®æœäŸïŒã®éŒ»çšã¹ãã¬ã€
çµæç©ãã¬ã©ã¹å®¹åšäžçªçŽ é°å²æ°äžã«30âã§ïŒã«
æ貯èµãããã·ãŠãŒãã¢ãã¹ã»ãšã«ã®ããŒã¶
ATCC9027ãã¹ã¿ãã€ãã³ãã«ã¹ã»ãªãŠã¬ãŠã¹
ATCC6538ãã¹ãã¬ããã³ãã«ã¹ã»ããªã²ãã¹
ATCC8668ããã³çèã®ã«ã³ãžãã»ã¢ã«ãã«ã³ã¹
ATCC10231ããµãã«ããã»ã¹ã»ã»ã¬ããµãš
ATCC9763ãã¢ã¹ãã«ã®ã«ã¹ã»ãã²ã«
ATCC16404ããã³ããã·ãªãŠã ã»ã¹ããã
ATCC10499ãå ããŠæ¥çš®æ¶²äžã®èæ°ãçŽïŒÃ105
åã«ãããïŒæé以å ã«ãèæ°ã¯0.1ïŒ ä»¥äžã«æž
å°ãããïŒé±é以å ã«ãèãèªããããªããªã€
ãã ããã«ãæšæºè©Šéšã«ãããšããã®çºæã®çµæç©
ã¯å¿å®¹æ§ããããäŸãã°ã·ãŠãã³ã¹çãActa
Otolaryng.70å·»26â27é ïŒ1970幎ïŒã®ãã€ã¯ãã
ãªããªã·ãã°ã©ãæ³ã«ãããšãæäžåŸ20åãŸã§çŽ°
æ¯æ¯ååæ°ã®æå¶ã¯50ïŒ ä»¥äžã§ãã€ãã æšæºèšåºè©Šéšã§ãåºãæèŠã¯ã»ãšãã©ãŸãã¯å š
ããªãã䜿çšäžæ±æã«å¯ŸããŠè¯å¥œãªå®å®æ§ã瀺ã
ãã 以äžãå®æœäŸã«ãããã®çºæã説æããã å®æœäŸ ïŒ éŒ»å æäžã«é©ãããµãŒã¢ã³ã«ã«ã·ããã³å«æçµ
æç©ã®è£œé ã æ å éïŒml (1) ãµãŒã¢ã³ã«ã«ã·ããã³ïŒæå¹æåïŒ10ïŒ
0.1375mg éå° 0.01375mg èš 0.15125mg (2) NaCl 7.5mg (3) å¡©åãã³ã¶ã«ã³ããŠã 0.1mg (4) HClïŒINïŒ å ããŠPH3.7ã«ãã (5) èžçæ°Ž æçµå®¹é1.0mlã«ãã æåïŒãªããïŒãçªçŽ ã¬ã¹äžã§åžžæ³ã«ããïŒæ
çµå®¹é2500mlãåŸãä»èŸŒéã§ïŒãµãŒã¢ã³ã«ã«ã·ã
ãã³10ïŒ ãéæ倱ãè£ãããã«å ããŠåãã
ãã次ãã§ïŒãå ããŠPH3.7ã«ããèžçæ°Žãå ã
ãŠæçµå®¹é2500mlã«ãããåŸããã溶液ãé
ïŒäŸãã°0.2ÎŒïœãã€ã«ã¿ãŒäœ¿çšïŒãã錻å é©çšã
ãã³æº¶æ¶²ïŒmlçšéŒ»çšã¹ãã¬ã€ãã€ã¹ãã³ãµãŒå å¡«
ã«é©ããçµæç©ãåŸãããã®çµæç©ã¯ãçŽ
550MRCåäœã®æå¹æåïŒmlãå«ã¿ãã¢ããªã±ãŒ
ã¿ãŒã¯ïŒåäœåœã55åäœãå«ãå®éãæŸåºããã å®æœäŸ ïŒ çžå¯Ÿççäœå å©çšæ§å®éšããµãŒã¢ã³ã«ã«ã·ãã
ã³ã®éŒ»å é©çšïŒçèå 泚å°ã äœé50ãªãã85Kgã®ç·æ§ïŒåã女æ§ïŒåãããª
ã12åã®å¿é¡è ã«ããè©Šéšãè¡ãªã€ããå被æ€è
ã¯ã«ã«ã·ããã³ã®ïŒåæäžãããªãã¡çèå æäž
ïŒåãšéŒ»å æäžïŒåãåãããæäžã¯äžèšçšéã§
è¡ãªã€ãã A.錻å A1.55MRCåäœ A2.110MRCåäœ A3.220MRCåäœ B.çèå 50MRCåäœ éŒ»å æäžã¯ãå®æœäŸïŒã®çµæç©ãšãåã¹ãã¬ã€
çšéåœã55MRCåäœãæŸåºããã¹ãã¬ã€ã¢ããª
ã±ãŒã¿ãŒãçšããŠè¡ãªã€ããæäžã®ããã«ã被æ€
è ã¯é éšãåŸæ¹ã«åŸããŠèäœã§ïŒåé暪ããã€
ããæäžçŽåã«éŒ»ãããã§éŒ»åãæž æããã çèå 泚å°ã¯ãå¡©åãã³ã¶ã«ã³ããŠã ãé€ãã
å€ã¯å®æœäŸïŒãšåæ§ãª50MRCåäœå«æçµæç©ïŒ
mlã®ïŒåçšéããäžæ®¿çã«æ³šå°ããŠè¡ãªã€ãã å被æ€è ã¯ïŒåã®æäžãç¡äœçºã®é åºã«åãã
åæäžã®éã«å°ãªããšãïŒæ¥éã®ééããããã
åæäžã¯ãæã®ãã«ã¯ããã¿ãŒãããŒãºããé€ã
ã軜ãæé£åŸã«è¡ãªã€ããå°¿ææ³ãä¿ã€ããã«ã
åŠçœ®åŸïŒæéæ¯ã«æ°ŽãŸãã¯ãªã¬ã³ãžãžãŠãŒã¹100
mlãäžãããåŠçœ®åŸïŒæéããããŠããé£ç©ãäž
ããã è¡æ¶²è©Šæã¯ãæäžçŽåïŒå¯Ÿç §ïŒããã³æäžåŸ
ïŒã15ã30ã60ã90ã120ã180ã240ã360ããã³
480åã«æ¡åãããå¯Ÿç §ã«ã¯20mlã以äžã®è©Šæã«
ã¯ïŒmlãæ¡åããã åè¡æž ãµã³ãã«äžã®ãµãŒã¢ã³ã«ã«ã·ããã³æ¿åºŠ
ã¯ãã©ãžãªã€ã ãã¢ãã»ã€ã«ãã枬å®ãããè©Šéš
äžã¯è¡å§ãå¶åŸ¡ããå¯äœçšã調ã¹ãããå°¿è©Šéã
æ¡åãããå¯äœçšãäŸãã°æªå¿ãèªããããã ãµãŒã¢ã³ã«ã«ã·ããã³è¡æŒ¿æ¿åºŠã«å¯ŸããAUC
ïŒæ²ç·äžé¢ç©ïŒããïŒåã¯26pïœïŒmlã®æ€åºéç
äžãå«ããŠå šéšã®å€ãçšããïŒåã¯æ€åºéçããŒ
ããšããå€ã®äžã«ãçµ±èšçã«èšç®ãããæé«è¡æŒ¿
æ¿åºŠããã³ãã®éææéã枬å®ããã錻å æäžã®
çžå¯Ÿççäœå å©çšæ§ã¯ã錻å ããã³çèå æäžåŸ
çžå¯ŸççšéâæšæºåAUCïŒ50MRCåäœã«åºã¥ãïŒ
ãã決å®ããã åŸãããçµæããã錻å 110ããã³220MRCå
äœæäžåŸã®AUCå€ãçèå 50MRCåäœæäžåŸã®
AUCå€ã«å¹æµãã錻å 110MRCåäœé©çšåŸïŒæ
éãŸã§ãµãŒã¢ã³ã«ã«ã·ããã³è¡æž ã¬ãã«ãæ€åºé
çå ã«æ®ãã®ã«å¯ŸããŠçèå 50MRCåäœé©çšã§
ã¯ïŒæéã§ããããšãããã€ãã220MRCåäœã®
æé«çšéã§ãã錻å æäžã§ã¯å¯äœçšãèªããããª
ãã€ãã å®æœäŸ ïŒ éŒ»å æäžã«é©ãããµãŒã¢ã³ã«ã«ã·ããã³å«æçµ
æç©ã®è£œé ã çµæç©çªå· 䜿çšãµãŒã¢ã³ã«ã«ã·ããã³é 3a 0.06875mgïŒml 3b 0.275mgïŒml 3c 0.55mgïŒml 3d 1.1mgïŒml çµæç©ã¯ãåéã®æåïŒããã³ïŒïŒãããã7.5
mgãŸãã¯0.1mgïŒmlïŒã䜿çšããæåïŒãçšããŠ
åãPH3.7ã«èª¿ç¯ããæåïŒãçšããŠå¿ èŠãªæçµ
容éã«ããããšã«ãããå®æœäŸïŒãšåæ§ã«è£œé ã
ããåŸãããçµæç©ã¯ãïŒmlåœãçŽ250ïŒçµæç©
3aïŒã1000ïŒ3bïŒã2000ïŒ3cïŒããã³4000ïŒ3dïŒ
MRCåäœã®æå¹æåãå«ã¿ãïŒåäœåœã0.2mlã®
æå¹æåãçµæç©3aã3bã3cããã³3dã«å¯Ÿãã
ããã25ã100ã200ããã³400MRCåäœïŒåäœã
ãæŸåºãã錻çšã¹ãã¬ã€ãã€ã¹ãã³ãµãŒã«å å¡«ã
ããå¿è«ã掻æ§ã®ç°ãªããµãŒã¢ã³ã«ã«ã·ããã³ã
䜿çšããå Žåã«ã¯ãMRCã§èŠå®ããå¿ èŠæ¿åºŠã®
éæã®ããã«ç°ãªã€ãéãå¿ èŠãšããã å®æœäŸ ïŒ éŒ»å æäžã«é©ãããµãŒã¢ã³ã«ã«ã·ããã³ãšéã€
ãªã³çé¢æŽ»æ§å€å«æçµæç©ã®è£œé ã äžèšæåãè¿œå ãã以å€ã¯ãå®æœäŸïŒãšåæ§ã«
ããŠçµæç©ã補é ããã
ãè¡šã
çµæç©ã¯å®æœäŸïŒèšèŒãšåæ§ã«éŒ»çšã¢ããªã±ãŒ
ã¿ãŒã«å ¥ããã å®æœäŸ ïŒ å®æœäŸïŒããã³4aã®çµæç©ã®çäœå å©çšæ§ã®
æ¯èŒã çµæç©ïŒãŸãã¯4a0.2mlãããµãŒã¢ã³ã«ã«ã·ã
ãã³çŽ100MRCåäœïŒããã®çšéã§éŒ»çšã¹ãã¬ã€
ã¢ããªã±ãŒã¿ãŒãçšããŠãããããã«çµéŒ»æäž
ïŒ0.1mlïŒéŒ»åïŒãããã®åŸïŒæéãµãŒã¢ã³ã«ã«ã·
ããã³ã®è¡æŒ¿äžã¬ãã«ã枬å®ãããåçµæç©æ¯ã«
ïŒåã®å®éšãè¡ãªããçµæãåãããŠã°ã©ãã«ã
ããããããçµæïŒå³é¢ïŒã¯ãäž¡çµæç©ã®çäœå
å©çšæ§ïŒæ²ç·äžé¢ç©AUCïŒãå®è³ªçã«çããã
å®æœäŸ4aã®çµæç©ã®æ¹ãæé«å€ã®éæã幟åæ©
ãããšã瀺ããã
ã¿ãŒã«å ¥ããã å®æœäŸ ïŒ å®æœäŸïŒããã³4aã®çµæç©ã®çäœå å©çšæ§ã®
æ¯èŒã çµæç©ïŒãŸãã¯4a0.2mlãããµãŒã¢ã³ã«ã«ã·ã
ãã³çŽ100MRCåäœïŒããã®çšéã§éŒ»çšã¹ãã¬ã€
ã¢ããªã±ãŒã¿ãŒãçšããŠãããããã«çµéŒ»æäž
ïŒ0.1mlïŒéŒ»åïŒãããã®åŸïŒæéãµãŒã¢ã³ã«ã«ã·
ããã³ã®è¡æŒ¿äžã¬ãã«ã枬å®ãããåçµæç©æ¯ã«
ïŒåã®å®éšãè¡ãªããçµæãåãããŠã°ã©ãã«ã
ããããããçµæïŒå³é¢ïŒã¯ãäž¡çµæç©ã®çäœå
å©çšæ§ïŒæ²ç·äžé¢ç©AUCïŒãå®è³ªçã«çããã
å®æœäŸ4aã®çµæç©ã®æ¹ãæé«å€ã®éæã幟åæ©
ãããšã瀺ããã
å³é¢ã¯ããµãŒã¢ã³ã«ã«ã·ããã³100MRCåäœã
ãããããïŒïœïŒïŒïŒã«çµéŒ»æäžããåŸã®ãµãŒã¢
ã³ã«ã«ã·ããã³è¡æŒ¿æ¿åºŠã瀺ãã
ãããããïŒïœïŒïŒïŒã«çµéŒ»æäžããåŸã®ãµãŒã¢
ã³ã«ã«ã·ããã³è¡æŒ¿æ¿åºŠã瀺ãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ () ã«ã«ã·ããã³ãããã³ () å¡©åãã³ã¶ã«ã³ããŠã ãã () 錻ç²èã«é©çšããã«é©ãã液äœåžéå€ãŸã
ã¯æ äœäžã«å«ãŸããŠãªãã 錻å æäžçšæ¶²å€ã ïŒ å¡©åãã³ã¶ã«ã³ããŠã ãçŽ0.002ãªããçŽ
0.02ïŒ ïŒééïŒå®¹éïŒã®æ¿åºŠã§ååšãããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¶²å€ã ïŒ ããã«ïŒïŒéŒ»ç²èã«é©çšããã«é©ããçé¢
掻æ§å€ãå«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒãŸãã¯ïŒé èš
èŒã®æ¶²å€ã ïŒ éŒ»çšã¹ãã¬ã€ã®åœ¢ã§æäžããã«é©åãããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒãªããïŒé ã®äœããïŒã€ã«èšèŒ
ã®æ¶²å€ã ïŒ ïŒïŒããµãŒã¢ã³ã«ã«ã·ããã³ãã²ãšã«ã«ã·
ããã³ãè±ã«ã«ã·ããã³ããã³ãšã«ã«ããã³ã®çŸ€
ããéžã°ãããã®ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒãª
ããïŒé ã®äœããïŒã€ã«èšèŒã®æ¶²å€ã ïŒ ïŒïŒãæ°Žãå«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒãªã
ãïŒé ã®äœããïŒã€ã«èšèŒã®æ¶²å€ã ïŒ ïŒïŒãé£å¡©æ°Žãå«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é èšèŒã®æ¶²å€ã ïŒ ïŒïŒãçŽ100ãªããçŽ8000MRCåäœïŒmlã®
éã§ååšãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒãªããïŒé ã®
äœããïŒã€ã«èšèŒã®æ¶²å€ã ïŒ ïŒïŒãçŽ500ãªããçŽ4000MRCåäœïŒmlã®
éã§ååšãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¶²
å€ã ïŒïŒ ïŒïŒãçŽ500ãªããçŽ2500MRCåäœã®é
ã§ååšãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¶²å€ã ïŒïŒ ïŒïŒãçŽ1000ãªããçŽ2000MRCåäœïŒ
mlã®éã§ååšãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒ
ã®æ¶²å€ã ïŒïŒ ïŒïŒããµãŒã¢ã³ã«ã«ã·ããã³ã§ãããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒãªããïŒïŒé ã®äœããïŒã€ã«èš
èŒã®æ¶²å€ã ïŒïŒ PHãçŽïŒãªããçŽïŒã§ãããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒãªããïŒïŒé èšèŒã®æ¶²å€ã ïŒïŒ PHãçŽ3.5ãªããçŽ4.5ã§ãããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒïŒé èšèŒã®æ¶²å€ã ïŒïŒ ææã®PHãåŸãæ段ãšããŠå¡©é žãå«ããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒãŸãã¯ïŒïŒé èšèŒã®æ¶²å€ã ïŒïŒ 滲éå§ãçŽ260ãªãã380ïœOsïœïŒãªãã
ã«ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒãªããïŒïŒé ã®äœ
ããïŒã€ã«èšèŒã®æ¶²å€ã ïŒïŒ ç²åºŠãïŒÃ10-3PaSããå°ããã¹ãã¬ã€ã«
ããæäžçšã®ãã®ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒãª
ããïŒïŒé ã®äœããïŒã€ã«èšèŒã®æ¶²å€ã ïŒïŒ å«æçµæç©ã錻ç²èã«é©çšãåŸãæ段ãå
ãã容åšã«é©å¿ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®æ¶²å€ã ïŒïŒ 容åšãã¹ãã¬ã€ã®åœ¢ã§çµæç©ã錻ç²èã«é©
çšãåŸãæ段ãåãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé
èšèŒã®æ¶²å€ã ïŒïŒ 容åšã錻çšãšã¢ããŸã«ã¢ããªã±ãŒã¿ãŒã§ã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®æ¶²å€ã
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8228390 | 1982-10-05 | ||
| GB8228390 | 1982-10-05 | ||
| GB8236928 | 1982-12-30 | ||
| GB8320865 | 1983-08-03 | ||
| GB8322528 | 1983-08-22 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2060862A Division JPH07103043B2 (ja) | 1982-10-05 | 1990-03-12 | ã«ã«ã·ããã³çµæç©ããã³ãã®çšé |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5989619A JPS5989619A (ja) | 1984-05-23 |
| JPH0354647B2 true JPH0354647B2 (ja) | 1991-08-20 |
Family
ID=10533387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58186648A Granted JPS5989619A (ja) | 1982-10-05 | 1983-10-04 | ã«ã«ã·ããã³çµæç©ããã³ãã®çšé |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS5989619A (ja) |
| BE (1) | BE897904A (ja) |
| ZA (1) | ZA837451B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL70489A0 (en) * | 1982-12-29 | 1984-03-30 | Armour Pharma | Pharmaceutical compositions containing calcitonin |
| JPS60161924A (ja) * | 1984-02-01 | 1985-08-23 | Fujisawa Pharmaceut Co Ltd | èºåžåçšçµæç© |
| JPS61194034A (ja) * | 1985-02-25 | 1986-08-28 | Teijin Ltd | çµéŒ»æäžçšç²æ«ç¶çµæç© |
| JPH0651637B2 (ja) * | 1985-03-28 | 1994-07-06 | ãšãŒã¶ã€æ ªåŒäŒç€Ÿ | ããã¿ã€ãã®åžçé²æ¢çµæç© |
| IL91856A0 (en) * | 1988-10-11 | 1990-06-10 | Schiapparelli Salute Spa | Pharmaceutical compositions comprising calcitonin for intranasal administration and a spray unit for the administration of the same |
| WO1999033490A1 (fr) | 1997-12-26 | 1999-07-08 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicinales a liberation prolongee |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56100714A (en) * | 1980-01-16 | 1981-08-12 | Teijin Ltd | Pharmaceutical adhering to oral mucous membrane or nasal mucous membrane |
| JPS56122309A (en) * | 1980-03-03 | 1981-09-25 | Teijin Ltd | Calcitonin pharmaceutical for rectal administration |
| JPS58189118A (ja) * | 1982-04-30 | 1983-11-04 | Takeda Chem Ind Ltd | çµéŒ»æäžè£œå€ |
| JPS59130820A (ja) * | 1982-12-29 | 1984-07-27 | ã¢âãâã»ãã¢âãã·ãŠâãã€ã«ã«ã»ã«ã³ããâ | è¡šé¢æŽ»æ§å€å«æçµæç©ã«ãã錻å éšãžã®ã«ã«ã·ããã³åžåã®ä¿é² |
-
1983
- 1983-10-04 JP JP58186648A patent/JPS5989619A/ja active Granted
- 1983-10-04 BE BE1/10881A patent/BE897904A/fr not_active IP Right Cessation
- 1983-10-05 ZA ZA837451A patent/ZA837451B/xx unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56100714A (en) * | 1980-01-16 | 1981-08-12 | Teijin Ltd | Pharmaceutical adhering to oral mucous membrane or nasal mucous membrane |
| JPS56122309A (en) * | 1980-03-03 | 1981-09-25 | Teijin Ltd | Calcitonin pharmaceutical for rectal administration |
| JPS58189118A (ja) * | 1982-04-30 | 1983-11-04 | Takeda Chem Ind Ltd | çµéŒ»æäžè£œå€ |
| JPS59130820A (ja) * | 1982-12-29 | 1984-07-27 | ã¢âãâã»ãã¢âãã·ãŠâãã€ã«ã«ã»ã«ã³ããâ | è¡šé¢æŽ»æ§å€å«æçµæç©ã«ãã錻å éšãžã®ã«ã«ã·ããã³åžåã®ä¿é² |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5989619A (ja) | 1984-05-23 |
| BE897904A (fr) | 1984-04-04 |
| ZA837451B (en) | 1985-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5733569A (en) | Galenic compositions comprising calcitonin and their use | |
| US6461591B1 (en) | Medical aerosol formulations | |
| EP0760649B1 (en) | Fluticasone propionate formulations | |
| US5902789A (en) | Nasal administration of drugs | |
| US5676931A (en) | Aerosol drug formulations for use with non CFC propellants | |
| GB2127689A (en) | Calcitonin inhalation compositions | |
| JP2521291B2 (ja) | çµéŒ»æäžçšæ°Žæ§ã¹ããã€ãè£œå€ | |
| US20040171666A1 (en) | Therapeutic compositions for intranasal administration which include KETOROLAC | |
| USRE43580E1 (en) | Nasal calcitonin formulations | |
| US5169849A (en) | Nasal pharmaceutical compositions | |
| BG63906B1 (bg) | ЀаÑЌаÑевÑОÑеМ аеÑПзПлеМ ÑÑÑÑав | |
| EP0370632B1 (en) | Pharmaceutical solution containing salbutamol and cromoglycic acid | |
| JPH0354647B2 (ja) | ||
| GB2162745A (en) | Nasal compositions | |
| EP1198224B1 (en) | Formulations of steroid solutions for inhalatory administration | |
| IE832339L (en) | Liquid nasal pharmaceutical composition | |
| IE56601B1 (en) | Galenic compositions comprising calcitonin and their use |